

REMARKS

A. Status of the Claims

Claims 9-18 were pending at the time of the Action. Claim 9 has been amended to correct a typographical error. New claims 19-21 have been added. Thus, claims 9-21 are currently pending. Because the amendment to claim 9 merely corrected a typographical error recognized by the examiner (*see* Action, p. 4) and the new claims merely recite a narrower subset of the antioxidants A and antioxidants B recited in claim 9, any new grounds for rejection cannot be based on Applicant's amendment. Thus, it would be improper for a subsequent Office Action to be made final if it includes any new grounds for rejection. *See* MPEP § 706.07(a).

B. Oath/Declaration

The Action asserts that a new oath or declaration is required because the declaration as filed in the application is not in the English language. This assertion is incorrect. The present application is a U.S. nationalization of a PCT application under 35 U.S.C. § 371, and a declaration in accordance with PCT Rule 4.17(iv) was provided. 37 C.F.R. § 1.69(b) states that in a U.S. nationalization of a PCT application under 35 U.S.C. § 371, a translation is not required of a declaration provided in accordance with PCT Rule 4.17(iv).

C. The Claims Satisfy the Requirements of 35 U.S.C. § 112, ¶ 1 and 2

The Action rejects claims 9-18 under 35 U.S.C. § 112, first paragraph, as failing to comply with the written description requirement, and under 35 U.S.C. § 112, second paragraph, as being indefinite. The Action's asserted basis for both rejections is that the specification does not define the chemical names for the antioxidants represented by the abbreviations NADH, NADPH, FADH₂, FMNH₂, FADH, and FMNH. Applicant traverses these rejections.

A proper evaluation of claims 9-18 under the second paragraph of 35 U.S.C. § 112 requires that the claims be read in light of the specification as interpreted by one of ordinary skill

in the art. *North Am. Vaccine, Inc. v. American Cyanamid Co.*, 7 F.3d 1571, 1579, 28 USPQ 2d 1333, 1339 (Fed. Cir. 1993). Whether a claim satisfies the written description requirement of the first paragraph of 35 U.S.C. § 112 is likewise determined from the perspective of a person of ordinary skill in the art. To satisfy the written description requirement, a patent specification must describe the claimed invention in sufficient detail that one skilled in the art can reasonably conclude that the inventors had possession of the claimed invention. *Vas-Cath, Inc. v. Mahurkar*, 935 F.2d 1555, 1563 (Fed. Cir. 1991). The current claims satisfy the requirements of 35 U.S.C. § 112, first and second paragraphs.

1. *Well-Known Terms of Art Do Not Require Detailed Definitions*

Use of well-known terms of art in the specification without detailed definitions does not render claims utilizing that same language indefinite. *W.L. Gore & Assoc., Inc. v. Garlock, Inc.*, 721 F.2d 1540, 1556-58 (Fed. Cir. 1983). Claims may, therefore, make use of the language understood by those of skill in the art without additional, detailed definitions in the written description. *Id.* As described in more detail below, the terms NADH, NADPH, FADH₂, FMNH₂, FADH, and FMNH are well-known terms that are readily understood by those in the art. Thus, these terms do not require detailed definitions in the specification.

2. *The Terms NADH, NADPH, FADH₂, FMNH₂, FADH, and FMNH Would Be Understood by Any Person Who Has Taken an Entry-Level Biochemistry Course*

The Action clearly failed to examine the claims from the perspective of a person of ordinary skill in the art, as the terms NADH, NADPH, FADH₂, FMNH₂, FADH, and FMNH are well-known terms that are readily understood by those in the art. In fact, these terms would even be understood by those who have only taken an entry-level biochemistry course.

NADH, NADPH, FADH₂, FMNH₂, FADH, and FMNH are commonly used abbreviations for nicotinamide adenine dinucleotide, reduced form; nicotinamide adenine

dinucleotide phosphate, reduced form; flavin adenine dinucleotide, reduced form; flavin mononucleotide, reduced form; flavin adenine dinucleotide, radical form; and flavin mononucleotide, radical form; respectively. It is readily apparent from standard biochemistry text books that these abbreviations are commonly used and understood in the art. For example, attached as Exhibit B to the Declaration of Dr. Pfannhauser ("Pfannhauser Declaration") (attached as Appendix A to this paper) is a table entitled "Some Common Biochemical Abbreviations" from Voet & Voet, BIOCHEMISTRY, 2d Ed., (John Wiley & Sons, Inc., 1995), which shows that NADH, NADPH, FADH₂, FADH, and FMN are well-known abbreviations in biochemistry. In fact, such abbreviations are used preferentially in Voet & Voet. If a person were to look up, for example, "nicotinamide adenine dinucleotide, reduced form" in the index of Voet & Voet that person would be directed to "see NADH." The same is true of NADPH, FADH₂, FADH, and FMN. A highlighted copy of the relevant pages of the index is attached as Exhibit C to the Pfannhauser Declaration. Although the reduced and radical forms of FMN are not listed in the index, the terms FMNH₂ and FMNH are used in Voet & Voet at, for example, page 575 (Exhibit D to the Pfannhauser Declaration). Another undergraduate-level biochemistry text, Streyer, BIOCHEMISTRY, 3d Ed. (W.H. Freeman and Co., 1988) contains a table entitled "Common Abbreviations in Biochemistry," which lists NADH, NADPH, FADH₂, FMNH₂, FAD, and FMN. A copy of this table is attached as Exhibit E to the Pfannhauser Declaration.

NADH, NADPH, FADH₂, FMNH₂, FADH, and FMNH are components of energy metabolism pathways (Pfannhauser Declaration, para. 5). NADH and FADH₂ are the major electron carriers in the oxidation of fuel molecules (Pfannhauser Declaration, para. 10). FAD may be fully reduced to FADH₂ or half-reduced to FADH (Pfannhauser Declaration, para. 10). NADPH is the major electron donor in reductive biosynthesis (Pfannhauser Declaration, para. 10). FMN is a component of Complex I of the mitochondrial electron transport chain

(Pfannhauser Declaration, para. 10). FMNH₂ is the reduced form of FMN and FMNH is the radical form of FMN (Pfannhauser Declaration, para. 10).

As stated in the Pfannhauser Declaration, energy metabolism pathways are learned by university students in their entry-level biochemistry courses (Pfannhauser Declaration, para. 5). Thus, even first-year university students who have taken an entry-level biochemistry course would readily understand the meaning of the terms NADH, NADPH, FADH₂, FMNH₂, FADH, and FMNH.

The Pfannhauser Declaration further notes that is clear from the present specification that NADH, NADPH, FADH₂, FMNH₂, FADH, and FMNH are described in the context of energy metabolism and electron transfer (Pfannhauser Declaration, para. 10). The Pfannhauser Declaration concludes that in view of the description of NADH, NADPH, FADH₂, FMNH₂, FADH, and FMNH in the present specification and the common use of these well-known terms in the biochemistry field, there is no question that scientists (and even students) in this field would readily understand the meaning of NADH, NADPH, FADH₂, FMNH₂, FADH, and FMNH as recited in the present claims and specification. (Pfannhauser Declaration, para. 11).

3. *The Examiner Has Not Met His Burden*

In rejecting a claim under the written description requirement, the Examiner has the initial burden of presenting evidence or reasons why a person skilled in the art would not recognize in an Applicant's disclosure a description of the invention defined in the claims. *In re Wertheim*, 541 F.2d 257, 262 (CCPA 1976). Accordingly, the Examiner is required: (1) to set forth the claim limitation not described; and (2) to provide reasons why a person skilled in the art would not have recognized the description of the limitation in view of the disclosure of the application as filed. *Interim Guidelines for the Examination of Patent Applications Under 35*

U.S.C. 112, Paragraph 1. In making an indefiniteness rejection, the Examiner is required to provide an analysis as to why the claim is “vague and indefinite.” MPEP § 2173.02.

The only alleged reasoning provided to support the written description and definiteness rejections is that the abbreviations render the claims “totally unsearchable” because a person of ordinary skill in the art “would have no idea what one is searching and looking for.” (Action, p. 3; *see also* p. 4). It is unclear why the Examiner considers the terms NADH, NADPH, FADH₂, FMNH₂, FADH, and FMNH “totally unsearchable.” To demonstrate that these terms are in fact searchable, Applicant typed the search term “NADH” into the PubMed database on September 11, 2006. The search returned 39,521 articles. To obtain a more manageable number of results, the search was then limited to only those articles published in 2002 and in which “NADH” occurred in the title. With these limitations the search returned 124 articles. A copy of the search results is attached as Appendix B. Numerous results were also obtained when Applicant searched the PubMed database for any of the terms NADPH, FADH₂, FMNH₂, FADH, or FMNH. The Action’s unsupported assertion that the claims are “totally unsearchable” is clearly inaccurate. Thus, the Action did not meet its burden of establishing that the claims do not satisfy the definiteness and written description requirements.

4. Conclusion

For the reasons set forth above, the present claims are definite and supported by adequate written description. Applicant, therefore, requests the withdrawal of these rejections.

D. Claim Objections

Claim 10 is objected to under 37 C.F.R. § 1.75(c) as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant traverses this objection.


An antioxidant is a compound that inhibits oxidation by binding free oxygen radicals. As recited in claim 9, antioxidant A is NADH, NADPH, FADH₂, FMNH₂, FADH, or FMNH; and antioxidant B is chlorophyll and/or a reduced ferredoxin. An “oxygen-sequestering substance” is a substance, such as an oil, that reduces, or largely prevents, any contact between antioxidant A and oxygen (Specification, p. 6, ln. 1-22). As described in the specification, an “oxygen-sequestering substance” protects antioxidant A by preventing the *contact* of antioxidant A with oxygen, whereas another antioxidant (i.e., antioxidant C) protects antioxidant A by *reducing oxygen* before the oxygen can react with antioxidant A (p. 6, ln. 23-32). Thus, claim 10 is a proper dependent claim because it references claim 9 and specifies a further limitation, namely that the composition of claim 9 further comprise an oxygen-sequestering substance, which is not the same substance as antioxidant A or antioxidant B as defined in current claim 9.

E. Conclusion

Applicant believes this to be a complete reply to the Office Action dated June 21, 2006, and respectfully requests favorable consideration of the claims in view of the amendments and statements contained herein.

The Examiner is invited to contact the undersigned attorney with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,



Travis M. Wohlers
Reg. No. 57,423
Attorney for Applicant

(Customer No. 32425)
FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
512.536.5654 (voice)
512.536.4598 (fax)

Date: September 15, 2006

APPENDIX A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Behzad SADEGHI *et al.*

Group Art Unit: 1714

Serial No.: 10/535,330

Examiner: Anthony, Joseph David

Filed: May 18, 2005

Atty. Dkt. No.: SONN:073US

For: NADH/NADPH-CONTAINING COMPOUND

DECLARATION OF WERNER PFANNHAUSER, Ph.D.

I, Werner Pfannhauser, hereby declare as follows:

1. I am an Austrian citizen residing at Kreuzgasse 79, A - 1180 Vienna, Austria.
2. I am currently the head of the Institute of Food Chemistry and Technology at the Technical University of Graz in Graz, Austria. I have extensive experience in the fields of chemistry and biochemistry. A copy of my *Curriculum Vitae* is attached as Exhibit A.
3. I have reviewed the specification of the above-reference application, the currently pending claims, the amended set of claims, and the Office Action dated June 21, 2006.
4. I understand that the Examiner rejected claims 9-18 as being indefinite and lacking adequate written description. I understand that the Examiner asserts that because the specification does not define the chemical names for the abbreviations NADH, NADPH, FADH₂, FMNH₂, FADH, and FMNH, a person of ordinary skill in the art would not understand the meaning of these terms. I do not find this to be the case.

5. The terms NADH, NADPH, FADH₂, FMNH₂, FADH, and FMNH are well-known in the field of biochemistry as they are components of energy metabolism pathways. In my experience, both as a student and as a professor, energy metabolism pathways (*e.g.*, glycolysis, citric acid cycle, and oxidative phosphorylation) are taught to university students in their entry-level biochemistry courses. As evidence of this, I have attached as Exhibits B-G pages from two general biochemistry text books: Voet & Voet, BIOCHEMISTRY, 2d Ed., (John Wiley & Sons, Inc., 1995) and Stryer, BIOCHEMISTRY, 3d Ed. (W.H. Freeman and Co., 1988).

6. Exhibit B is a table entitled "Some Common Biochemical Abbreviations" from Voet & Voet, which shows that NADH, NADPH, FADH₂, FADH, and FMN are well-known abbreviations in biochemistry. Exhibit C contains pages from the index of Voet and Voet listing NADH, NADPH, FADH₂, FADH, and FMN. Although the reduced and radical forms of FMN are not listed in the index, FMNH₂ and FMNH are described in Voet & Voet at, for example, page 575 (Exhibit D). Exhibit E is a table from the Stryer text book entitled "Common Abbreviations in Biochemistry," which lists NADH, NADPH, FADH₂, FMNH₂, FAD, and FMN.

7. Exhibit F contains pages 785 to 788 from Voet & Voet and provides a summary of the major energy metabolism pathways. NADH, NADPH, and FADH₂ are specifically mentioned on these pages. I also note that they are referred to as "NADH," "NADPH," and "FADH₂" and not as "nicotinamide adenine dinucleotide, reduced form," "nicotinamide adenine dinucleotide phosphate, reduced form," and "flavin adenine dinucleotide, reduced form." FADH is described on pages 400-401 of Voet & Voet (Exhibit G). FMNH₂ and FMNH are described on page 575 of Voet & Voet (Exhibit D).

8. Accordingly, anyone who has taken an entry-level biochemistry course would readily understand the meaning of the terms NADH, NADPH, FADH₂, FMNH₂, FADH, and FMNH. Of course, scientists who conduct research in this field would also readily understand the meaning of these terms.

9. Although the compounds NADH, NADPH, FADH₂, FMNH₂, FADH, and FMNH may also be referred to as nicotinamide adenine dinucleotide, reduced form; nicotinamide adenine dinucleotide phosphate, reduced form; flavin adenine dinucleotide, reduced form; flavin mononucleotide, reduced form; flavin adenine dinucleotide, radical form; and flavin mononucleotide, radical for, respectively; it is has been my experience from the scientific literature and from communications with my colleagues and students that NADH, NADPH, FADH₂, FMNH₂, FADH, and FMNH are the more commonly used terms. The preferred use of the terms NADH, NADPH, FADH₂, FMNH₂, FADH, and FMNH is evident in Voet & Voet. For example, if a person looks up "nicotinamide adenine dinucleotide, reduced form" in the index of Voet & Voet (attached as Exhibit D) that person would be directed to "see NADH." The same is true of NADPH, FADH₂, FADH, and FMN.

10. From my review of the present specification, it is clear that NADH, NADPH, FADH₂, FMNH₂, FADH, and FMNH are described in the context of energy metabolism and electron transfer. As explained in the preceding paragraphs, it is well-known that NADH, NADPH, FADH₂, FMNH₂, FADH, and FMNH are components of energy metabolism pathways (see also Exhibits B-G). In particular, it is well-known that NADH and FADH₂ are the major electron carriers in the oxidation of fuel molecules, and that FAD may be fully reduced to FADH₂ or half-reduced to FADH. NADPH is the major electron donor in reductive biosynthesis. FMN is a

component of Complex I of the mitochondrial electron transport chain and FMNH₂ is the reduced form of FMN and FMNH is the radical form of FMN.

11. In view of the description of NADH, NADPH, FADH₂, FMNH₂, FADH, and FMNH in the present specification and the common use of these well-known terms in the biochemistry field, there is no question that scientists (and even students) in this field would readily understand the meaning of NADH, NADPH, FADH₂, FMNH₂, FADH, and FMNH as recited in the present claims and specification.

12. I declare that all statements made of my knowledge are true and all statements made on the information are believed to be true; and, further that these statements were made with knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under § 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of this application or any patent issued thereupon.

Date: 13.9.2006



Werner Plannhauser, Ph.D.

EXHIBIT A

O.Univ.Prof. Dr. Werner Pfannhauser
Institute of Food Chemistry and –technology, University of Technology Graz
A- 8010 Graz, Petersgasse 12/2
Private : A - 8081 Heiligenkreuz am Waasen
A - 1180 Wien, Kreuzgasse 79

CURRICULUM

7.6.1940	born in Vienna / Austria
2.6.1959	Matura BG XVIII Vienna
1.9.1963 - 31.8.1965	Employee (research contract) at Wienerberger Ziegelfabriks- und Baugesellschaft, Vienna, working at TGM (Higher technical School)
1.9.1963 - 31.8.1969	Assistsant at TGM (Higher Technical School), Department of Silica Techniques
1969	Grant for gifted students
1969 - 1971	Thesis at Institute of Analytical Chemistry (Univ.Prof. F. Hecht) University of Vienna
8.7.1971	Promotion
24.1.1971	Titel Engeneer (Ing)
16.8.1971 - 31.8.1993	Chemist, Senior Scientist (1974) and Vizedirector (1981) of Forschungsinstitut der Ernährungswirtschaft (Research Institute of the Food Industry), Vienna
1978	Research Grant of the City of Vienna
1979 - 1996	Secretary of the Federation of European Chemical Societies (FECS) Working Party of Food Chemistry (WPFC), now renamed Division of Food Chemistry
since 1994	Austrian Delegate in FECS / FCD
since 1984	Board Member of the Austrian Society of Analytical Chemistry (ASAC),
since 1991	Vice President of ASAC
7.12.1988	Habilitation for Analytical Chemistry ar Technical University of Vienna
since 1992	Chairman of the Working Party of Food Chemistry of the Austrian Chemical Society (GÖCh)
1.10.1993	Appointed as a Full Professor of Food Chemistry at the Technical University of Graz, Institute of Bio- and Food Chemistry
1995 - 1998	Scientific director of Lebensmittelversuchsanstalt and Forschungsinstitut der Ernährungswirtschaft, Vienna
September 1996	Editor of Ernährung / nutrition
1996 –2000	President of the Austrian Society of Nutrition (ÖGE)
11/2000	Head of the newly founded Institute of Food Chemistry and - technology

Private:

married with Dkfm. Gertraud Pfannhauser, born Gruber, 5 sons;
 Owner of a private consulting agency in Vienna

Distinctions:

1988 : Gold Medal of the Italian Society of Flavour Research (Societa Scienze Aromatizzanti SSA)

1994 : Silver Medal of Merit of The City of Vienna

PUBLIKATIONSLISTE

O. Univ. Prof. Dr. Werner Pfannhauser

Institut für Lebensmittelchemie und -technologie
TU-Graz
8010 Graz, Petersgasse 12/II

1991

W.Pfannhauser

Die Schwermetallbelastung der österreichischen Nahrung im internationalen Vergleich
Ernährungsforschung 36, 13, (1991)

W.Pfannhauser

Spurenelemente in der Nahrung
Österreichische Apotheker Zeitung 45, (13) 269 (1991)

1992

W. Pfannhauser

Das essentielle Spurenelement Selen : Bedeutung, Wirkung und Vorkommen in der Nahrung. I. Essentialität, Funktion und Aufnahme. Selengehalte in Böden, Pflanzen und Tieren.

Ernährung / nutrition 16, (9), 506 (1992)

Das essentielle Spurenelement Selen : Bedeutung, Wirkung und Vorkommen in der Nahrung. II. Selen und die Immunlage des Organismus

Ernährung / nutrition 16, (10) 567 (1992)

Das essentielle Spurenelement Selen : Bedeutung, Wirkung und Vorkommen in der Nahrung. III. Selenversorgung und Aufnahmedaten aus Österreich im Vergleich mit Daten aus anderen Ländern. Schlußfolgerungen.

Ernährung / nutrition 16, (11) 642 (1992)

1993

W.Pfannhauser

Volatiles formed during Extrusion Cooking of Cereals
Flavour and Frangrance Journal 8, 109, (1993)

W.Pfannhauser

Selenaufnahme in Europa
Proceedings „Defizit und Überschuß an Mengen- und Spurenelementen in der Ernährung. S 79 -94
Jena 1994

1994

W.Pfannhauser

Versorgungsstatus mit dem essentiellen Spurenelement Selen in Österreich
Lebensmittelchemie 48, 123 (1994)

G. Cvim, M. Murkovic, W. Pfannhauser
Zearalenon und Deoxynivalenol in österreichischem Getreide
Mitt. Hygiene (Bern) 85, 728 (1994)

H.Löw, M. Murkovic, W. Pfannhauser
Bestimmung von 2-Amino-3-methylimidazo[4,5-f]quinoilin (IQ) in Fleischprodukten
Proceedings Österreichische Chemietage 1994 Graz

Strigl A.W., Leitner E. u. Pfannhauser W.
Vorkommen und Analyse der Farbstoffe der Schwarzen Apfelbeere (*Aronia melanocarpa*)
8. Österreichische Chemikertage Graz, Proceedings, S. 97. (1994)

1995

W.Pfannhauser
Der Versorgungsstatus mit dem essentiellen Spurenelement Selen in Österreich
Lebensmittel- und Biotechnologie 1995, 17

A.W.Strigl, E.Leitner, W.Pfannhauser
Zur Bestimmung des „Farbwertes“ von Früchten und Beeren am Beispiel der
Schwarzen Apfelbeere (*Aronia melanocarpa*)
Lebensmittelchemie 49, 03 (1995)

M. Wilplinger, I. Schönsleben, W. Pfannhauser
Chrom in österreichischen Lebensmitteln
Z. Lebensm. Unters. Forsch. 201, 521 - 523 (1995)

A.W. Strigl, E. Leitner, W. Pfannhauser
Qualitative und Quantitative Analyse der Anthocyane in Schwarzer Apfelbeere
(*Aronia melanocarpa* Michx.Ell.) mittels TLC, HPLC und UV/VIS - Spektrometrie
Z. Lebensm. Unters. Forsch. 201, 266 (1995)

A.W. Strigl, E. Leitner, W. Pfannhauser
Die Schwarze Apfelbeere als natürliche Farbstoffquelle
Deut. Lebensm. Rdsch. 91, 177 (1995)

U.Pechanek, W.Pfannhauser, C. Holler, K.Irsigler, H.Pinscher
Chemical and physiological aspects of enzyme-modified fibre
Europ.J.Clin.Nutr. 49, Suppl. 3, 291 - 95 (1995)

Fuchs, A. Krämer-Schafhalter, S. Silhar, M. Kovac, W. Pfannhauser
Influence of particle size and solvents on anthocyanin extraction of black chokeberry
(*Aronia melanocarpa*)
Current Status and Future Trends in Analytical Food Chemistry
Proceedings of EURO FOOD CHEM VIII, Vienna, 1995, p.227
G.Sontag, W.Pfannhauser eds.; ISBN 3-900554-17-X

Fuchs, A. Krämer-Schafhalter, S. Silhar, M. Kovac, W. Pfannhauser
Reinigung von Anthocyanen aus der Schwarzen Apfelbeere (*Aronia melanocarpa* Nero) über Festphasen
13. HP-Forum Analytik, Wien, 22.-24.1.1996 (Poster)

Krämer-Schafhalter, H. Fuchs, A. Strigl, S. Silhar, M. Kovac, W. Pfannhauser
Process Consideration for Anthocyanin Extraction from Black Chokeberry (*Aronia melanocarpa* Ell.)
Presentation at the International Symposium on Natural Colorants, Acapulco, Mexico, 23.-27.1.1996

Strigl, A. Krämer-Schafhalter, H. Fuchs, M. Scharf, E. Leitner, W. Pfannhauser
Extraction and Analysis of the Anthocyanins in Black Chokeberry (*Aronia melanocarpa* MICHX. ELL.)
Proceedings of the 2nd International Symposium on Natural Colorants, Acapulco, Mexico, 1996

Krämer-Schafhalter, H. Fuchs, S. Silhar, M. Mariassyova, A. Kintlerova, M. Kovac und W. Pfannhauser
Gewinnung von Destillaten aus der schwarzen Apfelbeere (*Aronia melanocarpa*), Krasny Precimysl, in prep.

1996

Fuchs, A. Krämer-Schafhalter, S. Silhar, M. Mariassyova, A. Kintlerova, M. Kovac, W. Pfannhauser
Quality of dye from *Aronia melanocarpa* var. Nero and optimal extraction conditions, Bulletin PV (Bratislava), 35, 101-110 (1996)

M. Wilplinger, I. Schönsleben, W. Pfannhauser
Versorgungszustand der Österreicher mit dem Spurenelement Chrom
Z. Lebensm. Unters. Forsch. 203, 207 - 209 (1996)

S. Schlemitz, W. Pfannhauser
Bestimmung von nitrirten polyzyklischen aromatischen Kohlenwasserstoffen in Lebensmitteln mittels gaschromatographischer Analyse.
(Poster beim Deutschen Lebensmittelchemiker Tag 1995)
Lebensmittelchemie 50, 21 (1996)

M. Murkovic, A. Hillebrand, J. Winkler, W. Pfannhauser
Variability of vitamin E content in pumpkin seeds (*Cucurbita pepo* L.)
Z. Lebensm. Unters. Forsch. 202, 275 - 278 (1996)

S. Schlemitz, W. Pfannhauser
Monitoring of nitropolycyclic aromatic hydrocarbons in food using gas chromatography
Z. Lebensm. Unters. Forsch. 203, 61-64 (1996)

B.Siegmund, E.Leitner, H.Siegl, I.Mayer, W.Pfannhauser
Die Kombination instrumenteller und sensorischer Methoden zur Identifizierung
aromaaktiver Verbindungen in Fleisch
Mitt.Hygiene (Bern) 87, 296 - 306 (1996)

B.Siegmund, E.Leitner, I.Mayer, P.Farkas, J. Sadecka, W.Pfannhauser
Untersuchungen zur Problematik der Extraktion von Aromastoffen mit der simultanen
Destillation-Extraktion nach Lickens-Nickerson
Deut. Lebensm. Rdsch. 92, 286 (1996)

H.Fuchs, A. Krämer-Schafhalter, W.Pfannhauser, S. Silhar, M.Mariassiva,
A.Kintlerova, M.Kovac
Pigment from Aronia melanocarpa var. Nero and optimum extraction conditions
Bull. Potravín. Vysk. 35, 101 (1996)

S.Schlemitz, W.Pfannhauser
Analysis of nitro-PAHs in food matrices by on-line reduction and high performance
liquid chromatography
Food Additives and Contaminants 13, 969 - 977 (1996)

B.Siegmund, E.Leitner, I.Mayer, P.Farkas, J.Sadecka, W.Pfannhauser, M.Kovac
Untersuchungen zur Problematik der Extraktion von Aromastoffen mit der simultanen
Destillation-Extraktion nach Lickens-Nickerson
Deutsche-Lebensmittel-Rundschau, (1996), 92(9), 286-290.

S. Schlemitz, W. Pfannhauser
Analysis of nitro-PAHs in food matrices by on-line reduction and high performance
liquid chromatography
Food Additives and Contaminants, 8, 969-977, (1996)

Hillebrand, A., Murkovic, M., Winkler, J., und Pfannhauser, W.
Ein hoher Gehalt an Vitamin E und ungesättigten Fettsäuren als neues Zuchtziel des
Kürbiszüchters
Ernährung/Nutrition 20(10):525-527, 1996.

R. van Eckert, P. Rait, W.
S. Pfannhauser
Österreichische Datenbank für überempfindliche Personen
Ernährung/ Nutrition (1996) 20(9):472-473

Response of different gliadin preparations in commercial ELISA-Kits
R. van Eckert, U. Swaton, W. Pfannhauser
11th Meeting of the Working Group on Prolamin Analysis and Toxicity,
6.11.-8.11.1996, Tecklenburg, Deutschland (Poster)

Österreichische Datenbank für überempfindliche Personen

R. van Eckert, R. Rait, W. Pfannhauser

Internationaler Lebensmittelchemikertag, 12.9.1996, Freiburg im Breisgau, Deutschland (Poster)

Österreichische Datenbank für überempfindliche Personen

R. van Eckert, P. Rait, W. Pfannhauser

Österreichische Lebensmittelchemiker Tage, 12.9.-13.9.1996, Graz (Poster)

Anthocyanins of *Aronia melanocarpa*: analysis, stability, changes during treatment and storage

A. Krämer-Schafhalter, H. Fuchs, W. Pfannhauser, S. Šilhar, M. Máriássyová, A. Kintlerová, M. Kováč

Proceedings Symposium on Polyphenols and Anthocyanins as Food Colourants and Antioxidants, 15.11.1996, Wien (Poster)

The evaluation of the *Likens-Nickerson*-Extraction for the generation of aroma-extracts demonstrated at a convenient hen-broth, olfaction and electronic nose

B. Siegmund., E. Leitner, I. Mayer, W. Pfannhauser, P. Farkáš, J. Sádecká J., M. Kováč

3.11.-6.11.1996, Miami, USA (Poster)

Lebensmittelqualität - was ist das ?

W. Pfannhauser

Ernährung / nutrition 95, (1) 1 - 8 (1996)

1997

M. Murkovic, D. Wiltshko, W. Pfannhauser

Formation of α -Tocopherolquinone and α -Tocopherolquinone Epoxides in Plant Oil
Fett / Lipide 99, (5), 165 - 169 (1997)

B. Siegmund, E. Leitner, I. Mayer, W. Pfannhauser, P. Farkas, J. Sadecka, M. Kovac

5,6-Dihydro-2,4,6-trimethyl-4*H*-1,3,5- dithiazine - an aroma-active compound formed in course of the Likens-Nickerson extraction

Z. Lebensm. Unters. Forsch 205, 73 - 75 (1997)

M. Murkovic, M. Gailhofer, W. Steiner, W. Pfannhauser

Formation of zearalenone on wheat contaminated with *Fusarium graminearum* under controlled conditions

Z Lebensm Unters Forsch A 204 :39-42 (1997)

M. Wilplinger, W. Pfannhauser

Aktueller Versorgungszustand der Österreicher mit dem Spurenelement Chrom

Ernährung/Nutrition 21 (2) , 61-62 (1997)

M. Murkovic, M. Friedrich, W. Pfannhauser

Heterocyclic aromatic amines in fried poultry meat

Z Lebensm Unters Forsch A 205 347-350 (1997)

S. Schlemitz, W. Pfannhauser

Supercritical fluid extraction of mononitrated polycyclic aromatic hydrocarbons from tea - Correlation with the PAH concentration
Z Lebensm Unters Forsch A (1997) [in press]

Krämer-Schafhalter, H. Fuchs, A.W. Strigl, W. Pfannhauser

Die schwarze Apfelbeere zur Gewinnung von Naturfarbstoffen
Ernährung/Nutrition, 21 (6), 260-262 (1997)

M. Murkovic, S. Draxl, W. Pfannhauser

Vitamin B1 in österreichischem Getreide
Ernährung/Nutrition, 21 (6), 263-265 (1997),

P.Farkaš, J.Sádecká, M.Kováč, B.Siegmund, E.Leitner, W.Pfannhauser

Key Odourants of Pressure-Cooked Hen Meat
Food Chemistry, 60(4), 617 - 621 (1997)

R. van Eckert, P. Rait, W. Pfannhauser

Österreichische Datenbank für überempfindliche Personen
Lebensmittelchemie 51, (6) (1997)

Bildung von heterozyklischen aromatischen Aminen in gebratenem Putenfleisch

M. Murkovic, M. Friedrich, W. Pfannhauser
HP-Forum Analytik, 21.1.-23.1.1997, Wien (Poster)

Vitamin B1 in österreichischem Getreide

M. Murkovic, S. Draxl, W. Pfannhauser
HP-Forum Analytik, 21.1.-23.1.1997, Wien (Poster)

Can erucic acid be used as an indicator for adulteration of pumpkin seed oil with rape seed oil?

M. Murkovic, S. Draxl, J. Winkler, W. Pfannhauser
EURO FOOD CHEM IX, 24.9.-26.9.1997, Interlaken, Schweiz (Poster)

Bildung von 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridin (PhIP) einem Kanzerogen aus gebratenem Fleisch in Modellreaktionen

S. Geisler, M. Murkovic, W. Pfannhauser
Österreichische Lebensmittelchemiker Tage, 12.9.-13.9.1997, Graz (Poster)

Oxidationsprodukte von α -Tocopherol in Speiseöl

D. Wiltshko, M. Murkovic, W. Pfannhauser
Österreichische Lebensmittelchemiker Tage, 12.9.-13.9.1997, Graz (Poster)

Tocopherolchinon als Abbauprodukt von Vitamin E in Milch

C. Eixelsberger, M. Murkovic, W. Pfannhauser
Österreichische Lebensmittelchemiker Tage, 12.9.-13.9.1997, Graz (Poster)

Vitamin B1 in österreichischem Getreide

M. Murkovic, S. Draxl, W. Pfannhauser
2. Seggauer Analysentage, 19.6.-20.6.1997, Seggau/Leibnitz (Poster)

Heterocyclic aromatic amines in fried poultry meat

M. Murkovic, M. Friedrich, W. Pfannhauser
4th Symposium on Instrumental Analysis, 20.5-23.5.1997, Graz (Poster)

Bildung von heterozyklischen aromatischen Aminen in Modellsystemen
M. Murkovic, S. Geiszler, K. Fröhlich, W. Pfannhauser
GDCh-Hauptversammlung und 100-Jahrfeier der GÖCH, 7.9.-11.9.1997, Wien
(Poster)

Chromium content in Austrian diets
M. Wilpinger, W. Pfannhauser
FAO-Meeting, 3./4.4.1997, Budapest (Poster)

Chromium supply in Austria
Wilpinger M., Pfannhauser W.
EURO FOOD CHEM IX, 24.9.-26.9.1997, Interlaken, Schweiz (Poster)

Determination of oxygenated compounds in spirits using a miniaturised plasma
atomic emission detector
D. Platzer, E. Kahr, G. Knapp, E. Leitner, W. Pfannhauser
In Vino Analytica Scientia, 12.6.-14.6.1997, Bordeaux (Poster)

Determination of the sensorial properties of a convenient hen-broth
B. Siegmund, I. Mayer, E. Leitner, W. Pfannhauser, P. Farkaš, J. Sádecká, M. Kovác
5th Wartburg Aroma Symposium, 17.3.-20.3.1997, Eisenach, BRD (Poster)

The importance of a GC retention index database for flavour analysis demonstrated
at the identification of aroma-active compounds of recooked dried hen meat
Farkaš P., Pfannhauser W., Sádecká J., Pet'ka, M. Kovác, B. Siegmund, E. Leitner
5th Wartburg Aroma Symposium, 17.3.-20.3.1997, Eisenach, BRD (Poster)

Qualität, Stabilität und Applikation von Anthocyanen aus der Schwarzen Apfelbeere
(*Aronia melanocarpa* Nero)
H.Fuchs, A. Krämer-Schafhalter, S. Šilhar, M. Kovác, W. Pfannhauser
100-Jahrfeier GÖCH, 26. GDCh-Hauptversammlung, 7.9.-11.9.1997, Wien (Poster)

Characterisation of anthocyanin colorants from Chokeberry (*Aronia melanocarpa*) by
determination of quality parameters
H. Fuchs, A. Krämer-Schafhalter, S. Šilhar, M. Kovác, W. Pfannhauser
Euro Food Chem IX, 24.9.-26.9.1997, Interlaken, Schweiz (Poster)

Nahrungsmittel (Europäische Datenbank) in "Allergologie für die Praxis 5,
Mönchengladbach 1996"
R. van Eckert, W. Pfannhauser
Hrsg. W. Jorde, Dustri-Verlag Dr. Karl Feistle, Deisenhofen bei München, 1. Aufl.
1997 (Poster)

Determination of proteins with ELISA-Methods: Doubtful quantitative results?
R. van Eckert, W. Pfannhauser
Euro Food Chem IX, 24.9.-26.9.1997, Interlaken, Schweiz (Poster)

Kapillarelektrophoretische Trennung von Weizenprolaminen
R. van Eckert, H. Siegl, S. Zöchling, W. Pfannhauser

100-Jahrfeier GÖCH, 26. GDCH-Hauptversammlung, 7.9.-11.9.1997, Wien (Poster)

Antioxidantien und Gesundheit

W. Pfannhauser

Ernährung / nutrition 21, (11) 496 - 499 (1997)

Bestimmung des Fettgehaltes von Lebensmitteln durch Extraktion mit überkritischem Kohlendioxid

R. Melinz, S. Fister, W. Pfannhauser

Ernährung / nutrition 21, (12) 557 -561 (1997)

M. Wilplinger, W. Pfannhauser

Fragestellungen zur Magnesiumversorgung

Ernährung / nutrition 21, 321 – 23 (1997)

1998

Die elektronische Nase - eine neue Technik in der Lebensmittelsensorik

B. Siegmund, W. Pfannhauser

Ernährung/nutrition 22, 154-157 (1998)

Selengehalt in der Nahrung und dessen Zusammenhang zum Gehalt im Boden

M. Wilplinger, A. Sima, W. Pfannhauser

N. Lebensmittelchemie (1998) 52, 93 – 95

M. Wilplinger, W. Pfannhauser

Chromium in Tea Leaves

Metal Ions in Biology and Medicin 5, 327 – 331 (1998)

M. Wilplinger, S. Zöchling, W. Pfannhauser

Chrom im Boden und in der Nahrung

VitaMinSpur (1998) 13, 117-120

M. Wilplinger, U. Schaller, W. Pfannhauser

Versorgung mit Nickel an verschiedenen Standorten in Österreich

Z. Lebensm. Unters. Forsch. (im Druck)

P.M. Abuja, M. Murkovic, W. Pfannhauser

Antioxidant and Prooxidant Activities of Elderberry (*Sambucus nigra*) Extract in Low-Density Lipoprotein Oxidation

J. Agric. Food Chem 1998, 46, 4091 – 96

A. Krämer-Schafhalter, H. Fuchs, W. Pfannhauser

B. Solid – Phase Extraction (SFE) – a comparison of 16 Materials for the Purification of Anthocyanins from *Aronia melanocarpa* var. Nero

J. Sci. Food Agric. 1998, 78, 435 - 440

M. Murkovic, D. Steinberger, W. Pfannhauser

Antioxidant spices reduce the formation of heterocyclic amines in fried meat

Z. Lebensm. Unters. Forsch. A 207, 477 – 480 (1998)

1999

M.Murkovic, H.-J. Weber, S. Geißler, K. Fröhlich, W.Pfannhauser
Formation of the food associated carcinogen 2-amino-1-methyl[4,5-b]pyridine (PhIP)
in model systems
J.Food Chem 65, 233-237 (1999)

M. Wilplinger, S. Zöchling, W.Pfannhauser
An Analysis of the Manganese Supply in Austria on the Basis of a Selected Diet
Z. Lebensm. Unters. Forsch. A (1999) 208: 251 – 53

T. Wald, R van Eckert, A. Sima, W.Pfannhauser
Untersuchung der Gliadinuntergruppen österreichischer Weizensorten
Getreide Mehl und Brot 53, 1 (1999)

R. van Eckert, T. Wald, A. Sima, F. Repnegg, W.Pfannhauser
Immunochemische Untersuchungen von chromatographisch getrennten Gliadin –
Fraktionen
Lebensmittelchem. 53, 29 (1999)

B.Siegmund, W. Pfannhauser
Changes of the volatile fraction of cooked chicken meat during chill storage : results
obtained by the electronic nose in comparison to GC – MS and GC olfactometry
Z. Lebensm. Unters. Forsch. A (1999) 208; 336 – 341

B.Siegmund, E. Leitner, W.Pfannhauser
Development of a simple sample preparation technique for gas chromatographic-mass
spectrometric determination of nicotine in edible nightshades (Solanaceae)
J. Chromatography A 840, (1999) 249 – 260

B.Siegmund, E.Leitner, W.Pfannhauser
Determination of the Nicotine Content of Various Edible Nightshades (Solanaceae)
and Their Products and Estimation of the Associated Dietary Nicotine Intake
J.Agric. Food Chem. 1999, 47, 3113 – 3120

S. Porta, W.Temmel, T. Gifford, J.Rand, D.Westmoreland, A.Sima, W.Pfannhauser,
H. Bacher
Human field experiments about the interrelationship of Magnesium, electrolyte and
blood gas changes proportional to the intensity of accumulated workload – a
diagnostic approach
Magnesium Bulletin (1999) 3, 61 – 69

E.Leitner, W.Pfannhauser
Identification of aroma active compounds in cardboard using solid phase
microextraction (SME) coupled with GC-MS and GC-olfactometry
In Frontiers of Flavour Science, 2000
p- 74-78

2000

B. Siegmund, W. Pfannhauser

Chill storage of cooked chicken meat – changes in the volatile fraction observed by the electronic nose in comparison to GC-MS and GC-olfactrometry

In *Frontiers of Flavour Science*, 2000

p. 148 – 152

G. Leitner, D. Westmoreland, M. Knapp, K. Spencer, J. Merback, V. Kruzik, M. Weger, W. Pfannhauser, S. Porta

Stress induced electrolyte and blood gas changes with and without a six days oral treatment with elderberry (*Sambucus Nigra* L.) concentrate

Magnesium Bull. 22,(3), 72-76 (2000)

M. Murkovic, W. Pfannhauser

Stability of pumpkin seed oil

Eur. J. Lipid Sci. Technol. 102, 607 – 611 (2000)

M. Murkovic, H. Toplak, U. Adam, W. Pfannhauser

Analysis of Anthocyanins in Plasma for Determination of their Bioavailability

J. Food Comp. Anal. 13, 291-96 (2000)

M. Murkovic, K. Gams, S. Draxl, W. Pfannhauser

Development of an Austrian Carotenoid Database

J. Food Comp. Anal. 13, 435-40 (2000)

A. Sima, M. Wilplinger, S. Zöchling, S. Heumann, U. Schaller, W. Pfannhauser

Trace Elements in Austrian Food

Trace Elements in Man and Animal Nutrition No 10

Ed. A.M. Roussel, R.A. Anderson, A.E. Favier

Kluwer Academic / Plenum Publishers, New York, Boston, Dordrecht, London, Moscow, 2000

p. 239 – 241

W. Pfannhauser

Malnutrizione e micronutrienti : aspetti pratici in Austria

Malnutrizione – una sfida del terzo millennio per la società postindustriale – strategie di prevenzione e cura

Ed. L. Lucchin

Il Pensiero Scientifico Editore, Roma, 2000

p. 255 – 263

Murkovic M, Toplak H, Adam U, Pfannhauser W :

Analysis of anthocyanins in serum for determination of their bioavailability *Journal of Food Composition and Analysis*, 13 (2000) 435-440 (2000)

Murkovic M, Adam U, Pfannhauser W :

Analysis of anthocyanine glycosides in human serum Fresenius J Anal. Chem, Vol 366, pp 379-381 (2000)

Mülleder U, Murkovic M, Pfannhauser W :

Analysis of metabolites of cyanidinglucosides Czech J. Food Sci., 18 (2000) 189 (2000)

Murkovic M, Gams K, Draxl S, Pfannhauser W :

Development of an Austrian carotenoid database J. Food Comp. Analys. 13 (2000) 435-440 (2000)

2001

M. Murkovic, U. Mülleder, U. Adam, W. Pfannhauser

„Detection of anthocyanins from elderberry juice in human urine
J. Sci. Fd. Agric. 81: 934-37 (2001)

Simonova, W. Pfannhauser

Einfluß der Lagerbedingungen auf die Bildung biogener Amine in Fleisch, Fisch und Gemüse

Ernährung / nutrition 25: (6) 253-259 (2001)

Mülleder, U., Murkovic, M., Pfannhauser W. :

Metabolism of cyanidin glycosides of elderberry. 2001 Pfannhauser, W., Fenwick, G.r., Khokhar, S. Biologically-active Phytochemicals in Food: Analysis, Metabolism, Bioavailability and Function. Cambridge, RSC, (2001)

B. Siegmund, D. E. Leyden, E. Zikulnig, E. Leitner, M. Murkovic, W. Pfannhauser, H. Reif

The contribution of dietary nicotine and dietary cotinine to salivary cotinine levels as a nicotine biomarker

Food Chemistry 74 (2001), 259 – 265; (2001)

2002

Bandoniène D, Murkovic M, Pfannhauser W, Venskutonis PR, Gruzdiene D :

Detection and activity evaluation of radical scavenging compounds by using DPPG free radical and on-line HPLC-DPPH methods European Food Research and Technology, 214, 143-147 (2002)

Mülleder U, Murkovic M, Pfannhauser W :

Urinary excretion of cyanidin glycosides J. Biochem. Biophys Methods, 53, 61-66, 2002 (2002)

K. Riediger, W. Pfannhauser

Magnesium-, Calcium- und Kaliumversorgung bei österreichischen Grundwehrdienern

Ernährung/Nutrition, Vol 26/nr. 10 2002, 401 – 407, (2002)

C. Bandoniène, M. Murkovic, W. Pfannhauser, R.R. Venskutonis, d. Gruzdiene

Detection and activity evaluation of radical scavenging compounds by using DPPH free radical and on-line HPLC-DPPH methods

Eur Food Res Technol (2002) 214:143 – 147, (2002)

2003

B. Siegmund, R. Weiss, W. Pfannhauser

Sensitive method for the determination of nitrated polycyclic aromatic hydrocarbons in the human diet

Anal Bioanal chem. (2003) 375: 175-181

O. Bejaoui-Kefi, S. Sabbah, M. Murkovic, M. Dachraoui, W. Pfannhauser

Red wines anthocyanins analyses by HPLC using different detection modes

Ernährung/Nutrition, Vol 27/Nr. 5 2003, 197 – 207, (2003)

S. Siegmund, K. Derler, W. Pfannhauser

Chemical and sensory effects of glass and laminated carton packages on fruit juice products – Still a controversial topic

Swiss Society of Food Science and Technology. Published by Elsevier Ltd.,

Lebensm.-Wiss. u.-Technol. 37 (2004) 481 – 488, (2004)

2004

P. Bejaoui Kefi, S. Sabbah, M. Dachraoui and W. Pfannhauser

HPLC determination of free phenolic acids using electrochemical, UV and ESI-MS detection methods and their Application to Tunisian red wines

Ernährung/Nutrition Vol 28/Nr. 9 2004, 350 – 360, (2004)

T. Zierler, B. Siegmund, W. Pfannhauser

Determination of off-flavour compounds in apple juice caused by microorganisms using headspace solid phase microextraction-gas chromatography- mass spectrometry

Analytica Chimica Acta 520 (2004) 3-11

EXHIBIT B

DONALD VOET

University of Pennsylvania

JUDITH G. VOET

Swarthmore College

BIOCHEMISTRY

SECOND EDITION



JOHN WILEY & SONS, INC.

New York Chichester Brisbane

Toronto Singapore

Acquisitions Editor: *Nedah Rose*
Marketing Manager: *Catherine Faduska*
Designer: *Madelyn Lesure*
Manufacturing Manager: *Susan Stetzer*
Photo Researcher: *Hilary Newman*
Illustration Coordinator: *Edward Starr*
Illustrators: *J/B Woolsey Associates*
Production Management: *Pamela Kennedy Oborski and Suzanne Ingrao*
Cover and Part Opening Illustrations © *Irving Geis*
This book was set in 9.5/12 Times Roman by Progressive Information Technologies and printed and bound by Von Hoffman Press. The cover was printed by Lehigh Press Lithographers. Color separations by Lehigh Press Colortronics.

Cover Art: Two paintings of horse heart cytochrome *c* by Irving Geis in which the protein is illuminated by its single iron atom. On the front cover the hydrophilic side chains are drawn in green, and on the back cover the hydrophobic side chains are drawn in orange. The paintings are based on an X-ray structure by Richard Dickerson.

Recognizing the importance of preserving what has been written, it is a policy of John Wiley & Sons, Inc. to have books of enduring value published in the United States printed on acid-free paper, and we exert our best efforts to that end.

John Wiley & Sons, Inc., places great value on the environment and is actively involved in efforts to preserve it. Currently, paper of high enough quality to reproduce full-color art effectively contains a maximum of 10% recovered and recycled post-consumer fiber. Wherever possible, Wiley uses paper containing the maximum amount of recycled fibers. In addition, the paper in this book was manufactured by a mill whose forest management programs include sustained yield harvesting of its timberlands. Sustained yield harvesting principles ensure that the number of trees cut each year does not exceed the amount of new growth.



TOTAL 10% RECYCLED PAPER
ALL POST-CONSUMER WASTE

Copyright © 1995, by John Wiley & Sons, Inc.

All rights reserved. Published simultaneously in Canada.

Reproduction or translation of any part of this work beyond that permitted by Sections 107 and 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc.

ISBN: 0-471-58651-X

Printed in the United States of America

10 9 8 7 6 5 4 3 2

SOME COMMON BIOCHEMICAL ABBREVIATIONS^a

A	adenine	ER	endoplasmic reticulum
aa	amino acid	FAD	flavin adenine dinucleotide, oxidized form
aaRS	amino-acyl tRNA synthetase	FADH [•]	flavin adenine dinucleotide, radical form [•]
ACAT	acyl-CoA:cholesterol acyl transferase	FADH ₂	flavin adenine dinucleotide, reduced form
ACh	acetylcholine	FBP	fructose-1,6-bisphosphate
ACP	acyl carrier protein	FBPase	fructose-1,6-bisphosphatase
ADA	adenosine deaminase	Fd	ferredoxin
ADH	alcohol dehydrogenase	FH	familial hypercholesterolemia
ADP	adenosine diphosphate	fMet	<i>N</i> -formylmethionine
AIDS	acquired immunodeficiency syndrome	FMN	flavin mononucleotide [•]
AMP	adenosine monophosphate	F1P	fructose-1-phosphate
AMPK	AMP-dependent protein kinase	F6P	fructose-6-phosphate
ALA	δ -aminolevulinic acid	G	guanine
ATCase	aspartate transcarbamoylase	GABA	γ -aminobutyric acid
ATP	adenosine triphosphate	Gal	galactose
BChl	bacteriochlorophyll	GalNAc	<i>N</i> -acetylgalactosamine
bp	base pair	GAP	glyceraldehyde-3-phosphate
BPG	D-2,3-bisphosphoglycerate	GAPDH	glyceraldehyde-3-phosphate dehydrogenase
BPheo	bacteriopheophytin	GC	gas chromatography
BPTI	bovine pancreatic trypsin inhibitor	GDP	guanosine diphosphate
C	cytosine	Glc	glucose
CaM	calmodulin	GMP	guanosine monophosphate
cAMP	cyclic AMP	G1P	glucose-1-phosphate
CAP	catabolite gene activating protein	G6P	glucose-6-phosphate
cAPK	cAMP-dependent protein kinase	GPI	glycosylphosphatidyl inositol
cDNA	complementary DNA	GSH	glutathione
CDP	cytidine diphosphate	GSSG	glutathione disulfide
CDR	complementarity determining region	GTP	guanosine triphosphate
CE	capillary electrophoresis	HA	hemagglutinin
Chl	chlorophyll	Hb	hemoglobin
CM	carboxymethyl	HDL	high density lipoprotein
CMP	cytidine monophosphate	HGPRT	hypoxanthine-guanine phosphoribosyl transferase
CoA or CoASH	coenzyme A	HIV	human immunodeficiency virus
CoQ	coenzyme Q (ubiquinone)	HMG-CoA	β -hydroxy- β -methylglutaryl-CoA
CTP	cytidine triphosphate	hnRNA	heterogeneous nuclear RNA
D	dalton	HPLC	high-performance liquid chromatography
d	deoxy	hsp	heat shock protein
dd	dideoxy	Hyl	5-hydroxylysine
DEAE	diethylaminoethyl	Hyp	4-hydroxyproline
DG	<i>sn</i> -1,2-diacylglycerol	IDL	intermediate density lipoprotein
DHAP	dihydroxyacetone phosphate	IF	initiation factor
DHF	dihydrofolate	IgG	immunoglobulin G
DHFR	dihydrofolate reductase	IHP	inositol hexaphosphate
DMF	<i>N,N</i> -dimethylformamide	IMP	inosine monophosphate
DMS	dimethyl sulfate	IP ₁	inositol-1-phosphate
DNP	2,4-dinitrophenol	IP ₃	inositol 1, 4, 5-triphosphate
DNA	deoxyribonucleic acid	IPTG	isopropylthiogalactoside
Dol	dolichol	IR	infrared
L-DOPA	L-3,4-dihydroxyphenylalanine	IS	insertion sequence
EF	elongation factor	ITP	inosine triphosphate
EGF	epidermal growth factor	<i>K_m</i>	Michaelis constant
EPR	electron paramagnetic resonance	kb	kilo base pair

^a The three-letter and one-letter abbreviations for the "standard" amino acid residues are given in Table 4-1.

kD	kilodaltons	PRPP	5-phosphoribosyl- α -pyrophosphate
KF	Klenow fragment	PS	photosystem
LCAT	lecithin:cholesterol acyl transferase	PSTV	potato spindle tuber virus
LDH	lactate dehydrogenase	Q	ubiquinone (CoQ)
LDL	low density lipoprotein	QH ₂	ubiquinol
Man	mannose	r	ribo
Mb	myoglobin	RER	rough endoplasmic reticulum
MHC	major histocompatibility complex	RF	release factor <i>or</i> replicative form
mRNA	messenger RNA	RFLP	restriction-fragment length polymorphism
MS	mass spectrometry	RK	HMG-CoA reductase kinase
NA	neuraminidase	RNA	ribonucleic acid
NAD ⁺	nicotinamide adenine dinucleotide, oxidized form ^o	RNAP	RNA polymerase
NADH	nicotinamide adenine dinucleotide, reduced form ^o	R5P	ribose-5-phosphate
NADP ⁺	nicotinamide adenine dinucleotide, phosphate, oxidized form ^o	RPC	reverse phase chromatography
NADPH	nicotinamide adenine dinucleotide ^o phosphate, reduced form ^o	rRNA	ribosomal RNA
NAG	<i>N</i> -acetylglucosamine	RSV	Rous sarcoma virus
NAM	<i>N</i> -acetylmuramic acid	RT	reverse transcriptase
NANA	<i>N</i> -acetylneuraminic (sialic) acid	RTK	receptor tyrosine kinase
NER	nucleotide excision repair	Ru1,5P	ribulose-1,5-bisphosphate
NMN	nicotinamide mononucleotide	Ru5P	ribulose-5-phosphate
NMR	nuclear magnetic resonance	S	Svedberg unit
NOESY	nuclear Overhauser effect spectroscopy	SAM	<i>S</i> -adenosylmethionine
P or p	phosphate	SCID	severe combined immunodeficiency disease
P _i	orthophosphate ion	SDS	sodium dodecyl sulfate
PAGE	polyacrylamide gel electrophoresis	snRNA	small nuclear RNA
PBG	porphobilinogen	snRNP	small ribonuclear protein
PC	plastocyanin	S7P	sedoheptulose-7-phosphate
PCR	polymerase chain reaction	SRP	signal recognition particle
PE	phosphatidylethanolamine	T	thymine
PEP	phosphoenolpyruvate	TBP	TATA box-binding protein
PEPCK	PEP carboxykinase	TBSV	tomato bushy stunt virus
PFG	pulsed-field gel electrophoresis	TCA	tricarboxylic acid
PFK	phosphofructokinase	THF	tetrahydrofolate
PG	prostaglandin	TIM	triose phosphate isomerase
2PG	2-phosphoglycerate	TLC	thin layer chromatography
3PG	3-phosphoglycerate	TMV	tobacco mosaic virus
PDGF	platelet-derived growth factor	TPP	thiamine pyrophosphate
PGI	phosphoglucose isomerase	tRNA	transfer RNA
PGK	phosphoglycerate kinase	TS	thymidylate synthase
PGM	phosphoglycerate mutase	TTP	thymidine triphosphate
Pheo	pheophytin	U	uracil
PIP ₂	phosphatidylinositol-4,5-bisphosphate	UDP	uridine diphosphate
PK	pyruvate kinase	UDP-g	UDP-glucose
PKU	phenylketonuria	UMP	uridine monophosphate
PLP	pyridoxal-5-phosphate	UTP	uridine triphosphate
PNP	purine nucleotide phosphorylase	UV	ultraviolet
Pol	DNA polymerase	V _{max}	maximal velocity
PP _i	pyrophosphate ion	VLDL	very low density lipoprotein
PrP	prion protein	XMP	xanthosine monophosphate
		XP	xeroderma pigmentosum
		Xu5P	xylulose-5-phosphate
		YAC	yeast artificial chromosome
		YADH	yeast alcohol dehydrogenase

EXHIBIT C

DONALD VOET

University of Pennsylvania

JUDITH G. VOET

Swarthmore College

BIOCHEMISTRY

SECOND EDITION



JOHN WILEY & SONS, INC.

New York Chichester Brisbane

Toronto Singapore

Acquisitions Editor: *Nedah Rose*
Marketing Manager: *Catherine Faduska*
Designer: *Madelyn Lesure*
Manufacturing Manager: *Susan Stetzer*
Photo Researcher: *Hilary Newman*
Illustration Coordinator: *Edward Starr*
Illustrators: *J/B Woolsey Associates*
Production Management: *Pamela Kennedy Oborski and Suzanne Ingrao*
Cover and Part Opening Illustrations © *Irving Geis*
This book was set in 9.5/12 Times Roman by Progressive Information Technologies and printed and bound by Von Hoffman Press. The cover was printed by Lehigh Press Lithographers. Color separations by Lehigh Press Colortronics.

Cover Art: Two paintings of horse heart cytochrome c by Irving Geis in which the protein is illuminated by its single iron atom. On the front cover the hydrophilic side chains are drawn in green, and on the back cover the hydrophobic side chains are drawn in orange. The paintings are based on an X-ray structure by Richard Dickerson.

Recognizing the importance of preserving what has been written, it is a policy of John Wiley & Sons, Inc. to have books of enduring value published in the United States printed on acid-free paper, and we exert our best efforts to that end.

John Wiley & Sons, Inc., places great value on the environment and is actively involved in efforts to preserve it. Currently, paper of high enough quality to reproduce full-color art effectively contains a maximum of 10% recovered and recycled post-consumer fiber. Wherever possible, Wiley uses paper containing the maximum amount of recycled fibers. In addition, the paper in this book was manufactured by a mill whose forest management programs include sustained yield harvesting of its timberlands. Sustained yield harvesting principles ensure that the number of trees cut each year does not exceed the amount of new growth.



TOTAL 10% RECYCLED PAPER
ALL POST-CONSUMER WASTE

Copyright © 1995, by John Wiley & Sons, Inc.

All rights reserved. Published simultaneously in Canada.

Reproduction or translation of any part of this work beyond that permitted by Sections 107 and 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc.

ISBN: 0-471-58651-X

Printed in the United States of America

10 9 8 7 6 5 4 3 2

- complex with DNA, 1162
 Estrogen response element (ERE), 1162
 Estrogens, 703F, 1159, 1167, 1263T, 1269, 1272
 and HDL levels, 324–325
 ETF. *See* electron-transfer flavoprotein.
 ETF:ubiquinone oxidoreductase, 669F
 Ethanol, 53, 334F, 785
 from alcoholic fermentation, 466
 prochirality of, 66F
 Ethanolamine, 281T, 713–714F
 Ethanolamine kinase, 714F
 Ethanolamine plasmalogen, 716F
 Ethidium, 926
 Ethidium ion, 871F–872F, 877F–878F
 Ethylene, as a plant hormone, 1007
 Ethylene glycol, 180F
 O⁶-Ethylguanine, 1046
 N-Ethylmaleimide, 120F
 Ethylmethanesulfonate, 1053F
 Ethylnitrosourea, 961F
 Ethylthiofluoroacetate, 120F
 Euchromatin, 1032F, 1149
 Eukaryotes, 6–13
 cellular architecture of, 6–11
 Eukaryotic gene expression, 1123–1189
 European corn borer, 908
 Evans, M., 177
eve. *See* even-skipped gene.
 Eve protein, 1176
even-skipped gene (*eve*), 1175
 Evolution, by gene duplication, 131–132
 by gene duplication, 209–211
 by neutral drift, 125
 chemical, 21–22, 123–132
 convergent, 210, 394, 457
 Darwinian, 125
 divergent, 211, 457
 lines of descent, 12F
 organismal, 130–131
 rate of, 129–130F
 stages of, 19F, 20
 structural, 208–211
 through natural selection, 123–125
 Excisionase, 1100
 Excitatory synapses, 1296
 Exclusion limit, 83
 Exergonic processes, 47
 Exon transfer, 631–632F
 Exit site. *See* E-site.
 Exo conformation, 864–865F
 Exocrine gland, 1262
 Exocytosis, 8, 523F
 Exoglycosylases, 259
 Exonucleases, 883
 Exons, 946–948, 951, 954–955, 1143F–1146
 number of in proteins, 1146
 Exopeptidases, 108
 Exothermic processes, 43
 Expressed sequences. *See* exons.
 Expression vector, 906
 Extensive quantities, 52
 Extracellular-signal-regulated kinases (ERKs), 1285F–1286
 in Ras signaling cascade, 1286
 Extrinsic pathway, 1197F, 1205, 1206
 Extrinsic proteins. *See* peripheral proteins.
 Eyring, E., 348
 F-Actin, 1239F–1242F, 1245, 1251
 atomic model of, 1243–1244F
 image reconstruction of, 1239F
 model of S1 decoration, 1240
 Fab, crystallized with reverse transcriptase, 1042
 response to antigen binding, 1216–1218F
 X-ray structure of hemagglutinin complex, 1217–1218F
 X-ray structure of myohemerythrin segment complex, 1217–1218F
 Fab fragment, 1211F–1212, 1215F
 complexes with lysozyme, 1216–1217F
 Fabry's disease, 720T–721F
 Facilitated diffusion, 306, 514
 Factor B, 1230T, 1233
 Factor D, 1230T, 1233
 Factor H, 1230T, 1233
 Factor I (of complement system), 1230T, 1233
 Factor I. *See* fibrinogen.
 Factor II. *See* prothrombin.
 Factor III. *See* thromboplastin.
 Factor IV. *See* Ca²⁺
 Factor V. *See* proaccelerin.
 Factor VII. *See* proconvertin.
 Factor VIII. *See* antihemophilic factor.
 Factor IX. *See* Christmas factor.
 Factor X. *See* Stuart factor.
 Factor XI. *See* plasma thromboplastin antecedent.
 Factor XII. *See* Hageman factor.
 Factor XIII. *See* fibrin-stabilizing factor.
 Facultative chromatin, 1149
 FAD (flavin adenine dinucleotide, oxidized form), 400–401F, 731, 740, 787, 824F–825
 in β oxidation, 668–670F
 in dihydrolipoyl dehydrogenase, 543F, 544T
 in glycerophosphate shuttle, 567F
 in succinate dehydrogenase, 554–555F
 production of ATP through, 556
 FADH[•] (flavin adenine dinucleotide, radical form), 401F[•]
 FADH₂ (flavin adenine dinucleotide, reduced form), 401F, 787
 ATP yield from, 568–569
 FAD pyrophosphorylase, 824F–825
 FAICAR. *See* 5-Formaminoimidazole-4-carboxamide ribotide.
 Familial CJD, 1118
 Familial hypercholesterolemia (FH), 324, 701–702F
 and gene therapy, 908
 Family tree, human, 1144F
 Faraday constant (F), 43T, 435, 583
 Farber's lipogranulomatosis, 720T–721F
 Farnesyl pyrophosphate, 694–697F
 Farnesyl pyrophosphate synthase, 694
 Farnesylated proteins, 314F, 692F–693, 700
 Fasman, G., 202
 Fast atom bombardment, 117
 Fast-twitch muscle fibers, 469–470, 606
 Fat, brown. *See* brown adipose tissue.
 Fatal familial insomnia (FFH), 1118
 Fat cells. *See* adipocytes.
 Fats. *See* triacylglycerols.
 Fatty acid biosynthesis, 560, 680–688
 differences from β oxidation, 681F
 Fatty acid metabolism, 681F
 regulation of, 688, 690–691
 summary of, 787
 Fatty acids, 278–279, 666, 787, 789–792
 activation of, 667–668
 degradation of, 666–678
 desaturation of, 687–688
 elongation of, 687–688
 energetic yield on oxidation, 672
 metabolic fates of, 791
 odd-chain, 673–677
 physical properties of, 279
 transport into mitochondria, 668
 unsaturated, 272–273, 672–673, 687–688
 Fatty acyl synthase, 421, 635–639, 691F
 exons of, 1144–1145F
 mechanism of, 684F–686
 multifunctional enzyme, 683–685F
 Fatty acyl-ACP, 681F
 Fatty acylated proteins, 314
 Fatty acyl-CoA, 668–669F, 681F, 790
 Fatty acyl-CoA desaturases, 687–688F
 Fatty streak lesions, 325
 Fava bean, 622
 Favism, 622
 FBP. *See* fructose-1,6-bisphosphate.
 FBPhase. *See* Fructose-1,6-bisphosphatase.
 FBPhase-2. *See* fructose bisphosphatase-2.
 FCCP. *See* Carbonyl cyanide *p*-trifluoromethoxyphenylhydrazone.
 FC fragment, 1211F–1212, 1215F
 FDNB. *See* 1-fluoro-2,4-dinitrobenzene.
 FdUMP. *See* 5-Fluorodeoxyuridine.
 Feedback inhibition, 339
 Feher, G., 634
 Feigou, J., 1045
 Felsenfeld, G., 1152
 FeMo-cofactor, 778F–780
 Fe protein, 776, 778–781
 [4Fe–4S] cluster in, 778F
 X-ray structure of, 778F–780
 Fermentation, 5
 alcoholic, 333, 444F–445, 466–469
 homolactic, 444F–445, 464–466
 Ferredoxin, 574F, 640F–641F, 645, 655F, 780F
 Ferredoxin–NADP⁺ reductase, 640F–601, 645
 X-ray structure of, 645–646F
 Ferredoxin–thioredoxin reductase, 655F
 Ferritin, 273F
 Ferrocetate, 754–755F
 Ferryl oxidation state, 581F–582
 Fetal hemoglobin. *See* HbF.
 Feulgen reagent, 1124F
 F factor, 838
 F⁺ factor, 840–841, 918
 FFH. *See* fatal familial insomnia.
 F₁F₀ ATPase. *See* proton-translocating ATPase.
 FGAM. *See* formylglycinamide ribotide.
 FGAM synthetase, 798F
 FGAR. *See* formylglycinamide ribotide.
 FH. *See* familial hypercholesterolemia.
 Fibrin, 129

- breakdown of, 1206
 fibers of, 1198F–1200F
 formation of, 1198–1201
 Fibrinogen, 99, 129, 1197–1198T, 1206, 1207
 activation of, 1198–1201
 electron micrograph of, 1199F
 structure of, 1198–1199F
 Fibrinolysis, 1206
 Fibrin-stabilizing factor (FSF), 1197–1198T, 1200–1201, 1207
 Fibrinogen, 99, 129, 1197–1198T, 1206, 1207
 evolution of, 128–129F
 Fibroblast, 8F
 Fibroblast interferon, 1006
 Fibroin, 155
 Fibrous proteins. *See* proteins, fibrous.
 Fick's first law of diffusion, 514
 Fiers, W., 883
 50S subunit. *See* ribosomal large subunit.
 Figure-8 structure, 1054–1055F
 Filter binding assay, 1275
 Finch, J., 1127
 Fingerprinting, 91, 119, 391, 962
 Fink, G., 1065
 First committed step, 414–415
 First law of thermodynamics, 43–44, 627
 First-order rate constants, determination of, 346F
 First-order reactions, 346
 Fischer, E., 65, 245, 253, 333
 Fischer convention, 64–65, 253
 Fischer projections, 64F
 5S RNA, 930, 950F, 982T, 984–985F, 987F, 988–989T
 genes encoding, 1193F–1140F
 NMR structure of, 985F
 5.8S RNA, 989T, 1138F
 FK506, 200F–201, 1208
 FK506 binding protein (FK506BP), 200
 FK506BP. *See* FK506 binding protein.
 Flagella, 4
 bacterial, 1259–1260
 eukaryotic, 1256
 prokaryotic, 1234
 rotary motion of in bacteria, 1259F–1260
 structure of, 1260F
 Flagellar filament, 1259F
 Flagellar hook, 1259F
 Flagellin, 10, 1001, 1259
 H1, 1062–1064
 H2, 1062–1064
 FLAP. *See* 5-lipoxygenase-activating protein.
 Flavin adenine dinucleotide, oxidized form. *q*
 See FAD.
 radical form. *See* FADH.
 reduced form. *See* FADH.
 Flavin coenzymes, 337T–338T
 biosynthesis of, 825
 Flavin mononucleotide. *See* FMN.
 Flavins, 401, 746F–747
 Flavodoxin, 77F
 Flavokinase, 825F
 Flavoprotein dehydrogenase, 567F
 Flavoproteins, 401
 Flavoprotein, 401
 Fleming, A., 269
 Fletcher, R., 46
 Flippases, 306
 Flippase, 287F, 294, 306
 Flows,
 conjugate, 438
 nonconjugate, 438
 Flu. *See* influenza.
 Fluid mosaic model, 297–299
 Fluorescamine, 93, 94F
 Fluorescence, 630F, 631
 Fluorescence photobleaching recovery, 287–288F, 290
 Fluoride, 421
 Fluoroacetyl-CoA, 552F
 Fluorochlorobromomethane, 63F
 5-Fluorocytosine, 1066F–1067F
 5-Fluorodeoxyuridine, 814
 5-Fluorodeoxyuridylate (FdUMP), 813F, 815F, 828
 1-Fluoro-2,4-dinitrobenzene (FDNB), 119F, 120F, 1214
 Fluorophore, 288
 5-Fluorouracil, 814
 Fluoroprofen, 709F–710
 Fluoroacetate, toxicity of, 552F
 Fluorocitrate, inhibition of aconitase, 552F
 Flux, 439, 443, 470
 control by rate-determining step, 471
 control by substrate cycling, 474–475
 control of, 470–476
 generation of, 470–471
 variation of enzymatic rates with, 470–472
 Flux-generating enzymes, 439–440
 Flux-generating step, 470
 FMDV. *See* foot-and-mouth disease virus.
 FMet. *See* N-formylmethionine.
 FMN (flavin mononucleotide), 573F–575F, 804–805, 825F
 in Complex I, 573F, 575
 in redox loop mechanism, 584F
 oxidation states of, 575F
 Foam cells, 324
 Folate, 746F, 762F
 Foldback structures, 1136–1137F
 Folding accessory proteins, 198–202
 Folic acid, 338F
 Follicle-stimulating hormone (FSH), 1263T, 1271–1272F
 Food, energy content of, 663T
 Foot-and-mouth disease, 1086
 Foot-and-mouth disease virus (FMDV), 1087
 Footprinting, 922
 dimethyl sulfate, 895, 1057F
 DNase I, 1057F
 Force,
 driving, 438
 electromotive (emf), 435
 proton-motive (pmf), 583
 thermodynamic, 438
 Foreign genes, expression in animals, 423–424
 Forespore, 932
 N-Formimino glutamate, 742F
 Formaldehyde, 22
 Formamide, 744F
 5-Formaminoimidazole-4-carboxamide ribotide (FAICAR), 798F, 801
 N⁵-Formimino-THF, 739, 740F, 762T–763F
 N⁵-Formimino-THF cyclodeaminase, 763F
 Formate, 763F
 Formate dehydrogenase, 980
 Formylglycinamide ribotide (FGAR), 798F–800F
 Formylglycinamide ribotide (FGAM), 798F, 800F
 N-Formylkynurenine, 744F
 N-Formylmethionine (fMet), 67–68F, 991F
 removal of, 1007
 N-Formylmethionine-tRNA, 763F–764
 N¹⁰-Formyl-THF, 712T–713F, 762T–763F, 798F–799, 992
 Formyl-THF isomerase, 763F
 N¹⁰-Formyl-THF synthetase, 763F
 45S RNA, 950F, 1138F
 Fos protein, 1285F–1286
 in Ras signaling cascade, 44Fe–45S cluster, in aconitase, 551F
 Fowler's solution, 547
 Foxglove, purple, 526–527F
 F₀ particles, 587–590
 F₁ particles, 587–590
 X-ray structure of, 588–590
 F-pili, 838F
 Fractional saturation, 217
 Fragile X syndrome, 1068–1069
 Fragment I of prothrombin,
 X-ray structure of, 1203F
 Fragment reaction, 999
 Frameshift mutations, 962
 Frameshift suppressors, 981
 Frank, H., 177
 Franklin, B., 285
 Franklin, R., 851
 Free energy, 47–48
 concentration dependence of, 51–52
 of activation, 349–350
 of formation, 49, 50T
 of phosphate hydrolysis, 430T
 partial molar, 48
 work and, 48
 Freeman, H., 644
 Freeze-etch electron microscopy, 298–299F
 Freeze-fracture electron microscopy, 298–299F, 646
 Frictional coefficient, 89
 Frictional ratio, aa
 of proteins, 97T
 Fructofuranose, 254F
 β-Fructofuranosidase, 351
 See also α-D-glucosidase.
 Fructokinase, 476F–477
 Fructose, 253F, 450F
 furanose form of, 254F
 linear form of, 254F
 metabolism of, 476F–477
 Fructose bisphosphatase-2 (FBPase-2), 506–507, 789
 regulation of, 605T–606F
 inhibition by fructose-2,6-bisphosphatase (F2,6BP), 506F–507
 Fructose-1,6-bisphosphatase (FBPase), 341–342, 475, 491, 650F, 652, 654–655F, 788, 789
 in placentogenesis, 603–605F
 light activation of, 654–655F
 regulation of, 605T–606F

- globular heads of, 1236–1238F
heavy chain of, 1236T–1239
nonmuscle, 1250–1253
regulatory light chain (RLC) of, 1236T–1239
- Myosin–actin complex, atomic model of, 1244–1246
- Myosin light chain kinase (MLCK), 501F–502, 1249–1250F, 1252
in platelet contraction, 1252
pseudosubstrate peptide of, 502
- Myosin light chain phosphatase, 1249–1250F
- Myosin light chains, 1236T–1239
function of, 1243, 1249
- Myosin I, 1253F
- Myosin subfragment-1 (S1), 1238F–1241, 1245F–1248
model decorating F-actin, 1240F
X-ray structure of, 1238F–1239
- Myosin subfragment-2 (S2), 1238F–1239
- Myosin II, 1253F
- Myotonic dystrophy (DM), 1069
- Myristic acid, 278T
in fatty acylated proteins, 314
- Myosin subfragment-1, model decorating F-actin, 1240
X-ray structure of, 1238F–1239
- N regions, in heavy chain genes, 1221–1222
- n Protein. *See* priB protein.
- n⁺ Protein. *See* priA protein.
- n⁺ Protein. *See* priC protein.
- NA. *See* neuraminidase.
- (Na⁺–Ca²⁺) antiporter, cardiac, 527
- Na⁺ channels, 1293–1295
- Na⁺–glucose symport, 531–532F
mechanism of, 501F
- (Na⁺–K⁺). *See* (Na⁺–K⁺)–ATPase.
- (Na⁺–K⁺)–ATPase, 524–527, 789, 1292
conformational states of, 525–526F
function of, 525
inhibition by cardiac glycosides, 526–527
mechanism of, 525–526F
(Na⁺–K⁺) pump. *See* (Na⁺–K⁺)–ATPase.
- NAD⁺ (nicotinamide adenine dinucleotide, β -oxidized form), β 71, 172F, 334F, 785–787, 790, 792, 824F
in dihydrolipoyl dehydrogenase reaction, 543F–545
in DNA ligase reaction, 1029–1030F
mitochondrial transport of, 566–568
production of ATP through, 556
regeneration by fermentation, 444F–445, 464–470
- NAD⁺ kinase, 824F–825
- NAD⁺ pyrophosphorylase, 824F–825
- NAD⁺ synthetase, 824F–825
- NADH (nicotinamide adenine dinucleotide, β -reduced form), 334F, 785–787
ATP yield, 568–569
generation by glycolysis, 445, 457–459
mitochondrial transport of, 603–604F
- NADH–coenzyme Q reductase. *See* Complex I.
- NADH–cytochrome b₅ reductase, 688F
- NADH peroxidase, 406
- NADP⁺ (nicotinamide adenine β -dinucleotide phosphate, oxidized form), 334F, 786F–787, 824F
in photosynthesis, 628
- NADPH (nicotinamide adenine dinucleotide β -phosphate, reduced form), 834F, 414F, 599, 786F–787
as cellular reducing currency, 617
physiological distinction from NADH, 617
production by pentose phosphate pathway, 618F–619, 622
- NAG. *See* N-acetylglucosamine.
- NAM. *See* N-acetylmuramic acid.
- Namba, K., 1260
- NANA. *See* N-acetylneuraminic acid.
- nanos gene, 1174F–1175
- Nanos protein, 1174F–1175
- Napoleon Bonaparte, arsenic poisoning of, 547
- Naproxen, 709F
- Nathans, D., 884
- N-CAM. *See* Neural cell–adhesion molecule.
- Nearest-neighbor analysis, 913
- Negative cooperativity, 218
- Negative regulation, 934, 940
- N-end rule, 1014
- NER. *See* nucleotide excision repair.
- Nernst equation, 434–435, 437
- Nernst, W., 435
- Nernst–Planck equation, 514
- Nerve gases, 390–391, 1299
- Nerve growth factor (NGF) receptor, 1281F
- Nervonic acid, 278T
- Nervous system, 1207
- Neuberg, C., 445
- Neural cell–adhesion molecule (N-CAM), 1225F
- Neuraminidase (NA), 312, 1107F–1108T, 1112F–1113
antigenic variation of, 1112F–1113
carbohydrates of, 1112F–1113
X-ray structure of, 1112F–1113
- Neurohypophysis, 1263T, 1271F, 1274
- Neuromuscular junction, 1248
- Neuron, 11F
- Neuropeptides, 1301
- Neurotoxins, 1293–1295
- Neurotransmission, 1291–1301
- Neurotransmitters, 390–391, 1291
amino acids as, 1300–1301
inhibitory, 1300
polypeptides as, 1301
- Neutral drift, 125
- Neutral fats. *See* triacylglycerols.
- Neutron diffraction, 987
- Neutrophils, 1291
- Newman projection, 66F
- Newsholme, E., 475, 688
- Nexin, 1256F
- NF-1 gene, 1188
- NF-E1. *See* GATA-1.
- NF-E2, 1158
- NF-E3, 1158
- NF-E4, 1158
- Niacin. *See* nicotinic acid.
- Niacinamide. *See* nicotinamide.
- Nicholson, G., 297
- Nick translation, 1027F, 1031
- Nicking–closing enzyme. *See* type I topoisomerase.
- Nicotinamide, 334, 337F–338T, 824F, 1004, 1280F
- Nicotinamide adenine dinucleotide, β -oxidized form. *See* NAD⁺.
- Nicotinamide adenine dinucleotide, reduced form. *See* NADH.
- Nicotinamide adenine dinucleotide β -phosphate, oxidized form. *See* NADP⁺.
- Nicotinamide adenine dinucleotide β -phosphate, reduced form. *See* NADPH.
- Nicotinamide coenzymes, 337–338
biosynthesis of, 762, 764F–765
See also NAD⁺, NADH, NADP⁺, and NADPH.
- Nicotinamide mononucleotide (NMN), 824F–825
- Nicotinamide phosphoribosyl transferase, 824F–825
- Nicotinate, 824F
- Nicotinate adenine dinucleotide, 824F–825
- Nicotinate mononucleotide, 824F
- Nicotinate phosphoribosyl transferase, 824F–825
- Nicotine, 1296F
- Nicotinic acid, 337F
- Nicotinic receptors, 1296, 1301
- NIDDM. *See* non-insulin-dependent diabetes mellitus.
- Niedergerke, R., 1244
- Niemann–Pick disease, 720T–721F
- Nierhaus, K., 987
- Nigericin, 598
- NIH shift, 747–749F
- 9 + 2 assembly, 1256F
- Ninhydrin reaction, 81–82F
- Nirenberg, M., 963–964, 966
- Nitric oxide (NO),
as an intercellular messenger, 1290–1291
binding to hemoglobin, 217, 227, 233
- Nitrites, 598, 961
reaction with cytosine, 1049
- Nitrocellulose, 85, 94, 872–873, 903, 932, 965, 1275
- Nitrogenase, 776, 778–781
Fe protein of, 776, 778F–781
inactivation by O₂, 780
MoFe protein of, 778F–780
See also MoFe protein.
- Nitrogen fixation, 4, 776, 778–781
ATP requirement for, 780–781
electron flow in, 780F
- Nitrogen mustard, 961F
- Nitroglycerin, vasodilating effects of, 1290F
- 3-Nitro-2,5-hydroxypropionate, 555F
- p-Nitrophenolate, 389F–390F
- p-Nitrophenylacetate, 378F
hydrolysis by chymotrypsin, 389F–390F
- p-Nitrophenylhydrazonium, 1214F
- p-Nitrophenylguanidinobenzoate, 397F
- Nitrosamines, 961
- Nitrosoheme, 1291
- Nitrous acid, 961
- N-linked oligosaccharides, 271F–272, 609–615
core of, 271–272
cotranslational addition to proteins, 610–612
glycoforms of, 272

EXHIBIT D

DONALD VOET

University of Pennsylvania

JUDITH G. VOET

Swarthmore College

BIOCHEMISTRY

SECOND EDITION



JOHN WILEY & SONS, INC.

New York Chichester Brisbane

Toronto Singapore

Acquisitions Editor: *Nedah Rose*
Marketing Manager: *Catherine Faduska*
Designer: *Madelyn Lesure*
Manufacturing Manager: *Susan Stetzer*
Photo Researcher: *Hilary Newman*
Illustration Coordinator: *Edward Starr*
Illustrators: *J/B Woolsey Associates*
Production Management: *Pamela Kennedy Oborski and Suzanne Ingrao*

Cover and Part Opening Illustrations © *Irving Geis*
This book was set in 9.5/12 Times Roman by Progressive Information Technologies and printed and bound by Von Hoffman Press. The cover was printed by Lehigh Press Lithographers. Color separations by Lehigh Press Colortronics.

Cover Art: Two paintings of horse heart cytochrome *c* by Irving Geis in which the protein is illuminated by its single iron atom. On the front cover the hydrophilic side chains are drawn in green, and on the back cover the hydrophobic side chains are drawn in orange. The paintings are based on an X-ray structure by Richard Dickerson.

Recognizing the importance of preserving what has been written, it is a policy of John Wiley & Sons, Inc. to have books of enduring value published in the United States printed on acid-free paper, and we exert our best efforts to that end.

John Wiley & Sons, Inc., places great value on the environment and is actively involved in efforts to preserve it. Currently, paper of high enough quality to reproduce full-color art effectively contains a maximum of 10% recovered and recycled post-consumer fiber. Wherever possible, Wiley uses paper containing the maximum amount of recycled fibers. In addition, the paper in this book was manufactured by a mill whose forest management programs include sustained yield harvesting of its timberlands. Sustained yield harvesting principles ensure that the number of trees cut each year does not exceed the amount of new growth.



TOTAL 10% RECYCLED PAPER
ALL POST-CONSUMER WASTE

Copyright © 1995, by John Wiley & Sons, Inc.

All rights reserved. Published simultaneously in Canada.

Reproduction or translation of any part of this work beyond that permitted by Sections 107 and 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc.

ISBN: 0-471-58651-X

Printed in the United States of America

10 9 8 7 6 5 4 3 2

O_2 consumes twice as many moles of NADH as O_2 , the P/O ratio for NADH reoxidation at Region 2 is $90 \mu\text{mol of ADP} / (2 \times 15 \mu\text{mol of } O_2) = 3$; that is, 3 mol of ADP are phosphorylated per mole of NADH oxidized.

- (b) The experiment is continued by inhibiting electron transfer from NADH by rotenone and adding an additional $90 \mu\text{mol of ADP}$ (Fig. 20-12; Region 4), this time together with an excess of the FAD-linked substrate succinate. Oxygen consumption again continues until all the ADP is phosphorylated, and the system again returns to the resting state (Fig. 20-12; Region 5). Calculation of the P/O ratio for $FADH_2$ oxidation yields the value 2; that is, 2 mol of ADP are phosphorylated per mole of $FADH_2$ oxidized.
- (c) In the same manner, the oxidation of ascorbate/TPMP yields a P/O ratio of 1 (Fig. 20-12; Regions 6 and 7).

These conclusions agree with the inhibitor studies indicating that there are three entry points for electrons into the electron-transport chain and with the standard reduction potential measurements exhibiting three potential jumps, each sufficient to provide the free energy for ATP synthesis (Fig. 20-8).

The P/O Ratios May Be Subject to Revision

Measurements of P/O ratios are subject to systematic experimental errors for which it is difficult to correct, such as inaccuracies in the measurement of the oxygen concentration, the presence of AMP, and proton leakage from mitochondria. Thus, the widely accepted P/O values of 3, 2, and 1 associated with NADH-, $FADH_2$ -, and ascorbate/TPMP-linked oxidation may well be in error. Indeed, measurements by Peter Hinkle have yielded values close to 2.5, 1.5, and 1 for these quantities (we shall see in Section 20-3 that P/O ratios need not have integer values because the number of protons pumped out of the mitochondrion by any component of the electron transport chain may not be an integer multiple of the number of protons required to

synthesize ATP from $ADP + P_i$). If these values are correct, then the number of ATPs that are synthesized per molecule of glucose oxidized is $2.5 \text{ ATP/NADH} \times 10 \text{ NADH/glucose} + 1.5 \text{ ATP/FADH}_2 \times 2 \text{ FADH}_2/\text{glucose} + 2 \text{ ATP/glucose from the citric acid cycle} + 2 \text{ ATP/glucose from glycolysis} = 32 \text{ ATP/glucose}$ rather than the conventional value of 38 ATP/glucose implied by P/O ratios of 3, 2, and 1. However, since there is significant disagreement as to the validity of the revised P/O ratios, we shall, for the sake of consistency, use the more established values of 3, 2, and 1 throughout this textbook. You should nevertheless keep in mind that these values are disputed.

How the free energy of electron transport is actually coupled to ATP synthesis, a subject of active research, is discussed in Section 20-3. We first examine the structures of the four respiratory complexes in order to understand how they are related to the function of the electron-transport chain. Keep in mind, however, that as in most areas of biochemistry, this field is under intense investigation and much of the information we need for a complete understanding of these relationships has yet to be uncovered.

C. Components of the Electron-Transport Chain

Many of the proteins embedded in the inner mitochondrial membrane are organized into the four respiratory complexes of the electron-transport chain. Each complex consists of several protein components that are associated with a variety of redox-active prosthetic groups with successively increasing reduction potentials (Table 20-1). The complexes are all laterally mobile within the inner mitochondrial membrane; they do not appear to form any stable higher structures. Indeed, they are not present in equimolar ratios. In the following paragraphs, we examine their structures and the agents that transfer electrons between them. Their relationships are summarized in Fig. 20-13.




FIGURE 20-13. A diagram of the mitochondrial electron-transport chain indicating the pathway of electron transfer (black) and proton pumping (red). Electrons are transferred between Complexes I and III by the membrane-soluble CoQ


and between Complexes III and IV by the peripheral membrane protein cytochrome *c*. Complex II (not shown) transfers electrons from succinate to CoQ.

1. Complex I (NADH-Coenzyme Q Reductase)

Complex I passes electrons from NADH to CoQ. This probably largest protein component of the inner mitochondrial membrane (850 kD) contains one molecule of **flavin mononucleotide (FMN)**; a redox-active prosthetic group that differs from FAD only by the absence of the AMP group) and six to seven **iron-sulfur** clusters that participate in the electron-transport process (Table 20-1).

Iron-Sulfur Clusters Are Redox Active

Three types of iron-sulfur clusters are known to occur as prosthetic groups of **iron-sulfur proteins (nonheme iron proteins)**:



The two most common types, designated **[2Fe-2S]** and **[4Fe-4S]** clusters, consist of equal numbers of iron and sulfide ions and are both coordinated to four protein Cys sulphydryl groups. One means of identifying these clusters




FIGURE 20-14 The X-ray structure of ferredoxin from *Peptococcus aerogenes*, a monomeric 54-residue protein that contains two [4Fe-4S] clusters. The C α atoms of the four Cys residues liganding each [4Fe-4S] cluster are green, the Fe atoms are brown, and the S atoms are yellow. [Based on an X-ray structure by Elinor Adman, Larry Sieker, and Lyle Jensen, University of Washington.]

utilizes the fact that their sulfide ions are acid labile: They are released as H₂S near pH 1. The **[Fe-S]** cluster, which has been found only in bacteria, consists of a single Fe atom liganded to four Cys residues. Note that the Fe atoms in all three types of clusters are each coordinated by four S atoms, which are more or less tetrahedrally disposed around the Fe. (A [3Fe-4S] cluster, which has been found in only one bacterial species, resembles a [4Fe-4S] cluster that lacks an Fe atom.) The oxidized and reduced states of all iron-sulfur clusters differ by one formal charge regardless of their number of Fe atoms. This is because the Fe atoms in each cluster form a conjugated system and thus can have oxidation states between the +2 and +3 values possible for individual Fe atoms. For example, each of the two [4Fe-4S] clusters in the protein **ferredoxin** (Fig. 20-14) contains one Fe(II) and three Fe(III)'s in its oxidized form and two Fe(II)'s and two Fe(III)'s in its reduced form. Iron-sulfur proteins also occur in the photosynthetic electron-transport chains of plants and bacteria (Section 22-2); indeed, photosynthetic electron-transport chains are thought to be the evolutionary precursors of oxidative electron-transport chains (Section 1-4C).




FIGURE 20-15. The oxidation states of (a) FMN and (b) CoQ. Both coenzymes form stable semiquinone free radical states.

The Coenzymes of Complex I

FMN and CoQ, the coenzymes of Complex I, can each adopt three oxidation states (Fig. 20-15). Although NADH can only participate in a two-electron transfer, both FMN and CoQ are capable of accepting and donating either one or two electrons because their semiquinone forms are stable. In contrast, the cytochromes of Complex III (see below), to which reduced CoQ passes its electrons, are only capable of one-electron reductions. *FMN and CoQ therefore provide an electron conduit between the two-electron donor NADH and the one-electron acceptors, the cytochromes.*

CoQ's hydrophobic tail makes it soluble in the inner mitochondrial membrane's lipid bilayer. In mammals, this tail consists of 10 C₃ isoprenoid units and hence the coen-

zyme is designated Q₁₀. In other organisms, CoQ may have only 6 (Q₆) or 8 (Q₈) isoprenoid units.


2. Complex II (Succinate-Coenzyme Q Reductase)

Complex II, which contains the dimeric citric acid cycle enzyme succinate dehydrogenase (Section 19-3F) and three other small hydrophobic subunits, passes electrons from succinate to CoQ. It does so with the participation of a covalently bound FAD, one [4Fe-4S] cluster, two [2Fe-2S] clusters, and one cytochrome b₅₆₀ (Table 20-1). We discuss the structures of the cytochromes in connection with that of Complex III below. [One of Complex II's iron-sulfur clusters has a standard reduction potential that is too negative (−0.245 V) to accept electrons from succinate; its function is unknown.]

EXHIBIT E

BIOCHEMISTRY

THIRD EDITION



LUBERT STRYER

STANFORD UNIVERSITY



W. H. FREEMAN AND COMPANY / NEW YORK

Library of Congress Cataloging-in-Publication Data

Stryer, Lubert.
Biochemistry.

Includes index.

1. Biochemistry. I. Title.

QP514.2.S66 1988 574.19'2 87-36486

ISBN 0-7167-1843-X

ISBN 0-7167-1920-7 (international student ed.)

Copyright © 1975, 1981, 1988 by Lubert Stryer

No part of this book may be reproduced by any mechanical, photographic, or electronic process, or in the form of a phonographic recording, nor may it be stored in a retrieval system, transmitted, or otherwise copied for public or private use, without written permission from the publisher.

Printed in the United States of America

2 3 4 5 6 7 8 9 0 RRD 6 5 4 3 2 1 0 8 9 8

COMMON ABBREVIATIONS IN BIOCHEMISTRY

A	adenine	Hyp	hydroxyproline
ACP	acyl carrier protein	IgG	immunoglobulin G
ADP	adenosine diphosphate	Ile	isoleucine
Ala	alanine	IP ₃	inositol trisphosphate
AMP	adenosine monophosphate	ITP	inosine triphosphate
cAMP	cyclic AMP	LDL	low-density lipoprotein
cGMP	cyclic GMP	Leu	leucine
Arg	arginine	Lys	lysine
Asn	asparagine	Met	methionine
Asp	aspartate	NAD ⁺	nicotinamide adenine dinucleotide ⁺
ATP	adenosine triphosphate		(oxidized form)
ATPase	adenosine triphosphatase	NADH	nicotinamide adenine dinucleotide ⁻
C	cytosine		(reduced form)
CDP	cytidine diphosphate	NADP ⁺	nicotinamide adenine dinucleotide ⁺
CMP	cytidine monophosphate		phosphate (oxidized form)
CTP	cytidine triphosphate	NADPH	nicotinamide adenine dinucleotide ⁻
CoA	coenzyme A		phosphate (reduced form)
CoQ	coenzyme Q (ubiquinone)	PFK	phosphofructokinase
cyclic AMP	adenosine 3',5'-cyclic monophosphate	Phe	phenylalanine
cyclic GMP	guanosine 3',5'-cyclic monophosphate	P _i	inorganic orthophosphate
Cys	cysteine	PLP	pyridoxal phosphate
cyt	cytochrome	PP _i	inorganic pyrophosphate
d	2'-deoxyribo	Pro	proline
DNA	deoxyribonucleic acid	PRPP	phosphoribosylpyrophosphate
cDNA	complementary DNA	Q	ubiquinone (or plastoquinone)
DNase	deoxyribonuclease	QH ₂	ubiquinol (or plastoquinol)
EcoRI	EcoRI restriction endonuclease	RNA	ribonucleic acid
FAD	flavin adenine dinucleotide	mRNA	messenger RNA
	(oxidized form)	rRNA	ribosomal RNA
FADH ₂	flavin adenine dinucleotide ⁻	scRNA	small cytoplasmic RNA
	(reduced form)	snRNA	small nuclear RNA
fMET	formylmethionine	tRNA	transfer RNA
FMN	flavin mononucleotide (oxidized form)	RNase	ribonuclease
FMNH ₂	flavin mononucleotide (reduced form)	Rubisco	ribulose 1,5-bisphosphate carboxylase
G	guanine	Ser	serine
Gln	glutamine	T	thymine
Glu	glutamate	Thr	threonine
Gly	glycine	TPP	thiamine pyrophosphate
GDP	guanosine diphosphate	Trp	tryptophan
GMP	guanosine monophosphate	TTP	thymidine triphosphate
GSH	reduced glutathione	Tyr	tyrosine
GSSG	oxidized glutathione	U	uracil
GTP	guanosine triphosphate	UDP	uridine diphosphate
GTPase	guanosine triphosphatase	UDP-galactose	uridine diphosphate galactose
Hb	hemoglobin	UDP-glucose	uridine diphosphate glucose
HDL	high-density lipoprotein	UMP	uridine monophosphate
HGPRT	hypoxanthine-guanine phosphoribosyl transferase	UTP	uridine triphosphate
His	histidine	Val	valine
		VLDL	very low-density lipoprotein

EXHIBIT F

DONALD VOET

University of Pennsylvania

JUDITH G. VOET

Swarthmore College

BIOCHEMISTRY

SECOND EDITION



JOHN WILEY & SONS, INC.

New York Chichester Brisbane

Toronto Singapore

Acquisitions Editor: *Nedah Rose*
Marketing Manager: *Catherine Faduska*
Designer: *Madelyn Lesure*
Manufacturing Manager: *Susan Stetzer*
Photo Researcher: *Hilary Newman*
Illustration Coordinator: *Edward Starr*
Illustrators: *J/B Woolsey Associates*
Production Management: *Pamela Kennedy Oborski and Suzanne Ingrao*
Cover and Part Opening Illustrations © *Irving Geis*
This book was set in 9.5/12 Times Roman by Progressive Information Technologies and printed and bound by Von Hoffman Press. The cover was printed by Lehigh Press Lithographers. Color separations by Lehigh Press Colortronics.

Cover Art: Two paintings of horse heart cytochrome *c* by Irving Geis in which the protein is illuminated by its single iron atom. On the front cover the hydrophilic side chains are drawn in green, and on the back cover the hydrophobic side chains are drawn in orange. The paintings are based on an X-ray structure by Richard Dickerson.

Recognizing the importance of preserving what has been written, it is a policy of John Wiley & Sons, Inc. to have books of enduring value published in the United States printed on acid-free paper, and we exert our best efforts to that end.

John Wiley & Sons, Inc., places great value on the environment and is actively involved in efforts to preserve it. Currently, paper of high enough quality to reproduce full-color art effectively contains a maximum of 10% recovered and recycled post-consumer fiber. Wherever possible, Wiley uses paper containing the maximum amount of recycled fibers. In addition, the paper in this book was manufactured by a mill whose forest management programs include sustained yield harvesting of its timberlands. Sustained yield harvesting principles ensure that the number of trees cut each year does not exceed the amount of new growth.



TOTAL 10% RECYCLED PAPER
ALL POST-CONSUMER WASTE

Copyright © 1995, by John Wiley & Sons, Inc.


All rights reserved. Published simultaneously in Canada.

Reproduction or translation of any part of this work beyond that permitted by Sections 107 and 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc.

ISBN: 0-471-58651-X

Printed in the United States of America

10 9 8 7 6 5 4 3 2



25

Energy Metabolism: Integration and Organ Specialization

1. Major Pathways and Strategies of Energy Metabolism: A Summary
2. Organ Specialization
 - A. Brain
 - B. Muscle
 - C. Adipose Tissue
 - D. Liver
3. Metabolic Adaptation
 - A. Starvation
 - B. Diabetes Mellitus

1. MAJOR PATHWAYS AND STRATEGIES OF ENERGY METABOLISM: A SUMMARY

Figure 25-1 indicates the interrelationships among the major pathways involved in energy metabolism. Let us review these pathways and their control mechanisms.

1. Glycolysis (Chapter 16)

The metabolic degradation of glucose begins with its conversion to two molecules of pyruvate with the net generation of two molecules each of ATP and NADH. Under anaerobic conditions, pyruvate is converted to lactate (or, in yeast, to ethanol) so as to recycle the NADH. Under aerobic conditions, however, when glycolysis serves to prepare glucose for further oxidation, the NAD^+ is regenerated through oxidative phosphorylation (see below). The flow of metabolites through the glycolytic pathway is largely controlled by the activity of phosphofructokinase (PFK). This enzyme is activated by AMP and ADP, whose concentrations rise as the need for energy metabolism increases, and is inhibited by ATP and citrate, whose concentrations increase when the demand for energy metabolism has slackened. PFK is also activated by fructose-2,6-bisphosphate, whose concentration is regulated by the levels of glucagon, epinephrine, and norepinephrine through the intermediacy

At this point in our narrative we have studied all of the major pathways of energy metabolism. Consequently, we are now in a position to consider how organisms, mammals in particular, orchestrate the metabolic symphony to meet their energy needs. This chapter therefore begins with a recapitulation of the major metabolic pathways and their control systems, then considers how these processes are apportioned among the various organs of the body, and ends with a discussion of how the body deals with the metabolic challenge of starvation and how it responds to the loss of control resulting from diabetes mellitus.




FIGURE 25-1. The major energy metabolism pathways.

of cAMP (Section 17-3F). Liver and heart muscle F2,6P levels are regulated oppositely: A [cAMP] increase causes an [F2,6P] decrease in liver and an [F2,6P] increase in heart muscle.

2. Gluconeogenesis (Section 21-1)

Mammals can synthesize glucose from a variety of precursors, including pyruvate, lactate, glycerol, and glucogenic amino acids, through pathways that occur mainly in liver and kidney. Many of these precursors are converted to oxaloacetate which, in turn, is converted to

phosphoenolpyruvate and then, through a series of reactions that largely reverse the path of glycolysis, to glucose. The irreversible steps of glycolysis, those catalyzed by PFK and hexokinase, are bypassed in gluconeogenesis by hydrolytic reactions catalyzed, respectively, by fructose-1,6-bisphosphatase (FBPase) and glucose-6-phosphatase. FBPase and PFK may both be at least partially active simultaneously, creating a substrate cycle. This cycle, and the reciprocal regulation of FBPase and PFK, are important in regulating both the

direction of flux through glycolysis and gluconeogenesis (Sections 16-3 and 21-1B).

3. Glycogen degradation and synthesis (Chapter 17)

Glycogen, the storage form of glucose in animals, occurs mostly in liver and muscle. Its conversion to glucose-6-phosphate (G6P) for entry into glycolysis is catalyzed, in part, by glycogen phosphorylase, whereas the opposing synthetic pathway is mediated by glycogen synthase. These enzymes are reciprocally regulated through phosphorylation/dephosphorylation reactions as catalyzed by amplifying cascades that respond to the levels of the hormones glucagon and epinephrine through the intermediary of cAMP.

4. Fatty acid degradation and synthesis (Sections 23-1 through 23-5)

Fatty acids are broken down in increments of C_2 units through β oxidation to form acetyl-CoA. They are synthesized from this compound via a separate pathway. The activity of the β -oxidation pathway varies with the fatty acid concentration. This, in turn, depends on the activity of "hormone-sensitive" triacylglycerol lipase in adipose tissue that is stimulated, through cAMP-regulated phosphorylation/dephosphorylation reactions, by glucagon and epinephrine but inhibited by insulin. The fatty acid synthesis rate varies with the activity of acetyl-CoA carboxylase, which is activated by citrate and inhibited by the pathway product palmitoyl-CoA. Fatty acid synthesis is also subject to long-term regulation through alterations in the rates of synthesis of the enzymes mediating this process as stimulated by insulin and inhibited by fasting.

5. Citric acid cycle (Chapter 19)

The citric acid cycle oxidizes acetyl-CoA, the common degradation product of glucose, fatty acids, and ketogenic amino acids, to CO_2 and H_2O with the concomitant production of NADH and $FADH_2$. Many glucogenic amino acids can also be oxidized via the citric acid cycle through their breakdown to one of its intermediates (Section 24-3). The activities of the citric acid cycle regulatory enzymes, citrate synthase, isocitrate dehydrogenase, and α -ketoglutarate dehydrogenase, are controlled by substrate availability and feedback inhibition by cycle intermediates.

6. Oxidative phosphorylation (Chapter 20)

This mitochondrial pathway oxidizes NADH and $FADH_2$ to NAD^+ and FAD with the coupled synthesis of ATP. The rate of oxidative phosphorylation, which is tightly coordinated with the metabolic fluxes through glycolysis and the citric acid cycle, is largely dependent on the concentrations of ATP, ADP, and P_i .

7. Pentose phosphate pathway (Section 21-4)

This pathway functions to generate NADPH for use in reductive biosynthesis, as well as the nucleotide precursor ribose-5-phosphate, through the oxidation of G6P. Its flux-generating step is catalyzed by glucose-6-phosphate dehydrogenase, which is controlled by the level of NADP⁺. The ability of enzymes to distinguish between NADH, which is mainly utilized in energy metabolism, and NADPH permits energy metabolism and biosynthesis to be regulated independently.

8. Amino acid degradation and synthesis (Sections 24-1 through 24-5)

Excess amino acids may be degraded to common metabolic intermediates. Most of these pathways begin with an amino acid's transamination to its corresponding α -keto acid with the eventual transfer of the amino group to urea via the urea cycle. Leucine and lysine are ketogenic amino acids in that they can be converted only to acetyl-CoA or acetoacetate and hence cannot be glucose precursors. The other amino acids are glucogenic in that they may be, at least in part, converted to one of the glucose precursors — pyruvate, oxaloacetate, α -ketoglutarate, succinyl-CoA, or fumarate. Five amino acids are both ketogenic and glucogenic. Essential amino acids are those that an animal cannot synthesize itself; they must be obtained from plant and microbial sources. Nonessential amino acids can be synthesized by animals via pathways that are generally simpler than those synthesizing essential amino acids.

Two compounds lie at the crossroads of the foregoing metabolic pathways: acetyl-CoA and pyruvate (Fig. 25-1). Acetyl-CoA is the common degradation product of most metabolic fuels, including polysaccharides, lipids, and proteins. Its acetyl group may be oxidized to CO_2 and H_2O via the citric acid cycle and oxidative phosphorylation or used to synthesize fatty acids. Pyruvate is the product of glycolysis, the dehydrogenation of lactate, and the breakdown of certain glucogenic amino acids. It may be oxidatively decarboxylated to yield acetyl-CoA, thereby committing its atoms either to oxidation or to the biosynthesis of fatty acids. Alternatively, it may be carboxylated via the pyruvate carboxylase reaction to form oxaloacetate which, in turn, either replenishes citric acid cycle intermediates or enters gluconeogenesis via phosphoenolpyruvate, thereby bypassing an irreversible step in glycolysis. Pyruvate is therefore a precursor of several amino acids as well as of glucose.

The foregoing pathways occur in specific cellular compartments. Glycolysis, glycogen synthesis and degradation, fatty acid synthesis, and the pentose phosphate pathway are largely or entirely cytosolically based, whereas fatty acid degradation, the citric acid cycle, and oxidative phosphorylation occur largely in the mitochondrion. Different phases of gluconeogenesis and amino acid degradation occur in each of these compartments. The flow of metabolites across compartment membranes is mediated, in most cases, by specific carriers that are also subject to regulation.

The enormous number of enzymatic reactions that simultaneously occur in every cell (Fig. 15-1) must be coordinated and strictly controlled to meet the cell's needs. Such

regulation occurs on many levels. Intercellular communications regulating metabolism occur via certain hormones, including epinephrine, norepinephrine, glucagon, and insulin, as well as through a series of steroid hormones known as glucocorticoids (whose actions are discussed in Section 34-4A). These hormonal signals trigger a variety of cellular responses, including the synthesis of second messengers such as cAMP in the short term and the modulation of protein synthesis rates in the long term. On the molecular level, the enzymatic reaction rates are controlled by phosphorylation/dephosphorylation via amplifying reaction cascades, by allosteric responses to the presence of effectors, which are usually precursors or products of the reaction pathway being controlled, and by substrate availability. The regulatory machinery of opposing catabolic and anabolic pathways is generally arranged such that these pathways are reciprocally regulated.

2. ORGAN SPECIALIZATION

In this section we consider how the special needs of the mammalian body organs are met and how their metabolic capabilities are coordinated to meet these needs. In particular, we discuss brain, muscle, adipose tissue, and liver (Fig. 25-2).

A. Brain

Brain tissue has a remarkably high respiration rate. For instance, the human brain only constitutes ~2% of the adult body mass but is responsible for ~20% of its resting O_2 consumption. This consumption, moreover, is independent of the state of mental activity; it varies little between sleep and the intense concentration required of, say, the study of biochemistry. Most of the brain's energy pro-




FIGURE 25-2. The metabolic interrelationships among brain, adipose tissue, muscle, and liver. The red arrows indicate pathways that predominate in the well-fed state when glucose, amino acids, and fatty acids are directly available from the intestines.

EXHIBIT G

DONALD VOET

University of Pennsylvania

JUDITH G. VOET

Swarthmore College

BIOCHEMISTRY

SECOND EDITION



JOHN WILEY & SONS, INC.

New York Chichester Brisbane

Toronto Singapore

Acquisitions Editor: *Nedah Rose*
Marketing Manager: *Catherine Faduska*
Designer: *Madelyn Lesure*
Manufacturing Manager: *Susan Stetzer*
Photo Researcher: *Hilary Newman*
Illustration Coordinator: *Edward Starr*
Illustrators: *J/B Woolsey Associates*
Production Management: *Pamela Kennedy Oborski and Suzanne Ingrao*
Cover and Part Opening Illustrations © *Irving Geis*
This book was set in 9.5/12 Times Roman by Progressive Information Technologies and printed and bound by Von Hoffman Press. The cover was printed by Lehigh Press Lithographers. Color separations by Lehigh Press Colortronics.

Cover Art: Two paintings of horse heart cytochrome *c* by Irving Geis in which the protein is illuminated by its single iron atom. On the front cover the hydrophilic side chains are drawn in green, and on the back cover the hydrophobic side chains are drawn in orange. The paintings are based on an X-ray structure by Richard Dickerson.

Recognizing the importance of preserving what has been written, it is a policy of John Wiley & Sons, Inc. to have books of enduring value published in the United States printed on acid-free paper, and we exert our best efforts to that end.

John Wiley & Sons, Inc., places great value on the environment and is actively involved in efforts to preserve it. Currently, paper of high enough quality to reproduce full-color art effectively contains a maximum of 10% recovered and recycled post-consumer fiber. Wherever possible, Wiley uses paper containing the maximum amount of recycled fibers. In addition, the paper in this book was manufactured by a mill whose forest management programs include sustained yield harvesting of its timberlands. Sustained yield harvesting principles ensure that the number of trees cut each year does not exceed the amount of new growth.



**TOTAL 10% RECYCLED PAPER
ALL POST-CONSUMER WASTE**

Copyright © 1995, by John Wiley & Sons, Inc.

All rights reserved. Published simultaneously in Canada.

Reproduction or translation of any part of this work beyond that permitted by Sections 107 and 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc.

ISBN: 0-471-58651-X

Printed in the United States of America

10 9 8 7 6 5 4 3 2

inhibitor binds essentially irreversibly to any trypsin formed in the pancreas so as to inactivate it. Furthermore, the trypsin-catalyzed activation of trypsinogen (Fig. 14-26) occurs quite slowly, presumably because the unusually large negative charge of its highly evolutionarily conserved N-terminal hexapeptide repels the Asp at the back of trypsin's specificity pocket. Finally, pancreatic zymogens are stored in intracellular vesicles called **zymogen granules** whose membranous walls are thought to be resistant to enzymatic degradation.

Zymogens Have Distorted Active Sites


Since the zymogens of trypsin, chymotrypsin, and elastase have all their catalytic residues, why aren't they enzymatically active? Comparisons of the X-ray structures of trypsinogen with that of trypsin and of chymotrypsinogen with that of chymotrypsin show that upon activation, the newly liberated N-terminal Ile 16 residue moves from the surface of the protein to an internal position, where its free cationic amino group forms an ion pair with the invariant anionic Asp 194 (Fig. 14-21). Aside from this change, however, the structures of these zymogens closely resemble those of their corresponding active enzymes. Surprisingly, this resemblance includes their catalytic triads, an observation which led to the discovery that these zymogens are actually enzymatically active, albeit at a very low level. Careful comparisons of the corresponding enzyme and zymogen structures, however, revealed the reason for this low activity: *The zymogens' specificity pockets and oxyanion holes are improperly formed such that, for example, the amide NH of chymotrypsin's Gly 193 points in the wrong direction to form a hydrogen bond with the tetrahedral intermediate (see Fig. 14-25).* Hence, the zymogens' very low enzymatic activity arises from their reduced ability to bind substrate productively and to stabilize the tetrahedral intermediate. These observations provide further structural evidence favoring the role of transition state binding in the catalytic mechanism of serine proteases.

4. GLUTATHIONE REDUCTASE

Lysozyme and the serine proteases all catalyze hydrolytic reactions. In contrast, the third enzyme that we shall consider in mechanistic detail, **glutathione reductase**, catalyzes an oxidation–reduction reaction. Such reactions are extremely important in metabolic processes. We have chosen to study glutathione reductase, which sequentially catalyzes several electron-transfer processes, because it is one of the few such enzymes in which the pathway of electron flow has been well characterized.


Glutathione reductase is a nearly ubiquitous enzyme that catalyzes the NADPH-dependent reduction of **glutathione**

disulfide (GSSG) to glutathione (GSH):



(the structures of NADP⁺ and NADPH are indicated in Fig. 12-2). This process normally produces a GSH:GSSG ratio of over 100:1, which permits GSH to function as an intracellular reducing agent (the thermodynamics of oxidation–reduction reactions is discussed in Section 15-5). For example, the inactivation of proteins (P) that have free SH groups through the spontaneous oxidative formation of mixed disulfides

$\text{P-SH} + \text{P}'\text{-SH} + \frac{1}{2}\text{O}_2 \rightleftharpoons \text{P-S-S-P}' + \text{H}_2\text{O}$
is reversed through disulfide interchange with GSH.



GSH also acts as a coenzyme in several enzymatically catalyzed reductions and plays an important role in the transport of amino acids into certain cells (Section 24-4C).

FAD Is an Essential Redox Coenzyme

Glutathione reductase contains the electron-transfer prosthetic group **flavin adenine dinucleotide (FAD)**; (Fig. 14-28). **Flavins** (substances that contain the **isalloxazine ring**) can undergo two sequential one-electron transfers (Fig. 14-28), or a simultaneous two-electron transfer that bypasses the semiquinone state. The glutathione reductase reaction involves the simultaneous transfer of two electrons so that,




FIGURE 14-28. The molecular formula and reactions of the coenzyme flavin adenine dinucleotide (FAD). The term “flavin” is synonymous with the isoalloxazine ring system. The D-ribose residue is derived from the alcohol of the sugar D-ribose. FAD may be half-reduced to the stable radical FADH• or fully

reduced to FADH₂ (boxes). Consequently, different FAD-containing enzymes cycle between different oxidation states of FAD. FAD is usually tightly bound to its enzymes so that this coenzyme normally is a prosthetic group rather than a cosubstrate as is the case, for example, with NAD⁺.


in this case, the FAD never assumes its radical form. The oxidation state of the flavin in a **flavoprotein** (flavin-containing protein) is readily established from its characteristic UV-visible spectrum: FAD is an intense yellow, whereas FADH₂ is pale yellow.

Humans and other higher animals are unable to synthesize the isoalloxazine component of flavins, so they must obtain this substance from their diets, for example, in the form of riboflavin (vitamin B₂) (Fig. 14-28). Riboflavin deficiency is quite rare in humans, in part because of the tight binding of flavin prosthetic groups to their apoenzymes. The symptoms of riboflavin deficiency, which are associated with general malnutrition or bizarre diets, include an inflamed tongue, lesions in the corners of the mouth, and dermatitis.


Glutathione Reductase Catalyzes a Two-Stage Reaction

Glutathione reductase from human erythrocytes is a dimer of identical 478-residue subunits that are covalently linked by an intersubunit disulfide bond. In the absence of


GSSG, the enzyme catalyzes the first stage of a two-stage reaction:



where E represents fully oxidized glutathione reductase and EH₂ is a stable two-electron reduced intermediate whose chemical nature we shall presently discuss. Upon subsequent addition of GSSG, EH₂ reacts to form products and complete the catalytic cycle.



The glutathione reductase reaction is more complex than these overall reactions suggest. Vincent Massey and Charles Williams demonstrated that *oxidized glutathione reductase (E)* contains a “redox-active” disulfide bond, which in EH₂ has accepted an electron pair through bond cleavage to form a dithiol.



APPENDIX B



A service of the National Library of Medicine
and the National Institutes of Health

My NCBI
[Sign In] [Re]

All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

B

Search PubMed

for nadh

Go

Clear

Save S

☒ Limits

Preview/Index

History

Clipboard

Details

Field: Title, Limits: Publication Date from 2002 to 2002

Display Summary

Show 200

Sort by

Send to

All: 124

Review: 6

Items 1 - 124 of 124

One page.

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorials

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI

Related Resources

Order Documents

NLM Mobile

NLM Catalog

NLM Catalog

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

☐ 1: [Haldimann P, Tsimilli-Michael M.](#)

Related Articles, Links



Mercury inhibits the non-photochemical reduction of plastoquinone by exogenous NADPH and NADH: evidence from measurements of the polyphasic chlorophyll a fluorescence rise in spinach chloroplasts. *Photosynth Res.* 2002;74(1):37-50. PMID: 16228543 [PubMed - as supplied by publisher]

☐ 2: [Pagala VR, Park J, Reed DW, Hartzell PL.](#)

Related Articles, Links



Cellular localization of D-lactate dehydrogenase and NADH oxidase from *Archaeoglobus fulgidus*. *Archaea.* 2002 Sep;1(2):95-104. PMID: 15803647 [PubMed - indexed for MEDLINE]

☐ 3: [Kedar PS, Colah RB, Ghosh K, Mohanty D.](#)

Related Articles, Links



Congenital methemoglobinemia due to NADH-methemoglobin reductase deficiency in three Indian families. *Haematologia (Budap).* 2002;32(4):543-9. PMID: 12803131 [PubMed - indexed for MEDLINE]

☐ 4: [Averet N, Aguilaniu H, Bunoust O, Gustafsson L, Rigoulet M.](#)

Related Articles, Links



NADH is specifically channeled through the mitochondrial porin channel in *Saccharomyces cerevisiae*. *J Bioenerg Biomembr.* 2002 Dec;34(6):499-506. PMID: 12678441 [PubMed - indexed for MEDLINE]

☐ 5: [Birkmayer JG, Nadlinger K.](#)

Related Articles, Links











Safety of stabilized, orally absorbable, reduced nicotinamide adenine dinucleotide (NADH): a 26-week oral tablet administration of ENADA/NADH for chronic toxicity study in rats. *Drugs Exp Clin Res.* 2002;28(5):185-92. PMID: 12635493 [PubMed - indexed for MEDLINE]

















☐ 6: [Berrios-Rivera SJ, San KY, Bennett GN.](#)










Related Articles, Links



The effect of NAPRTase overexpression on the total levels of NAD, the NADH/NAD⁺ ratio, and the distribution of metabolites in *Escherichia coli*. *Metab Eng.* 2002 Jul;4(3):238-47. PMID: 12616693 [PubMed - indexed for MEDLINE]

- ☐ **7:** [Berrios-Rivera SJ, Bennett GN, San KY.](#) Related Articles, Links
 The effect of increasing NADH availability on the redistribution of metabolic fluxes in *Escherichia coli* chemostat cultures.
Metab Eng. 2002 Jul;4(3):230-7.
PMID: 12616692 [PubMed - indexed for MEDLINE]
- ☐ **8:** [Berrios-Rivera SJ, Bennett GN, San KY.](#) Related Articles, Links
 Metabolic engineering of *Escherichia coli*: increase of NADH availability by overexpressing an NAD(+)-dependent formate dehydrogenase.
Metab Eng. 2002 Jul;4(3):217-29.
PMID: 12616691 [PubMed - indexed for MEDLINE]
- ☐ **9:** [Zakharova NV, Zharova TV.](#) Related Articles, Links
 Kinetic mechanism of mitochondrial NADH:ubiquinone oxidoreductase interaction with nucleotide substrates of the transhydrogenase reaction.
Biochemistry (Mosc). 2002 Dec;67(12):1395-404.
PMID: 12600270 [PubMed - indexed for MEDLINE]
- ☐ **10:** [Nakano K, Takeo T, Sato T, Suga S, Eto K, Kadowaki T, Wakui M.](#) Related Articles, Links
 Role of mitochondrial NADH shuttle system in acute amylase secretion by acetylcholine from mouse pancreatic acinar cells.
Tohoku J Exp Med. 2002 Nov;198(3):151-62.
PMID: 12597242 [PubMed - indexed for MEDLINE]
- ☐ **11:** [Lo HC, Fish RH.](#) Related Articles, Links
 Biomimetic NAD(+) models for tandem cofactor regeneration, horse liver alcohol dehydrogenase recognition of 1,4-NADH derivatives, and chiral synthesis.
Angew Chem Int Ed Engl. 2002 Feb 1;41(3):478-81. No abstract available.
PMID: 12491384 [PubMed - indexed for MEDLINE]
- ☐ **12:** [Banta S, Anderson S.](#) Related Articles, Links
 Verification of a novel NADH-binding motif: combinatorial mutagenesis of three amino acids in the cofactor-binding pocket of *Corynebacterium* 2,5-diketo-D-gluconic acid reductase.
J Mol Evol. 2002 Dec;55(6):623-31.
PMID: 12486521 [PubMed - indexed for MEDLINE]
- ☐ **13:** [Okinaka Y, Yang CH, Herman E, Kinney A, Keen NT.](#) Related Articles, Links
 The P34 syringolide elicitor receptor interacts with a soybean photorespiration enzyme, NADH-dependent hydroxypyruvate reductase.
Mol Plant Microbe Interact. 2002 Dec;15(12):1213-8.
PMID: 12481993 [PubMed - indexed for MEDLINE]
- ☐ **14:** [Harmych S, Arnette R, Komuniecki R.](#) Related Articles, Links
 Role of dihydrolipoyl dehydrogenase (E3) and a novel E3-binding protein in the NADH sensitivity of the pyruvate dehydrogenase complex from anaerobic mitochondria of the parasitic nematode, *Ascaris suum*.
Mol Biochem Parasitol. 2002 Nov-Dec;125(1-2):135-46.
PMID: 12467981 [PubMed - indexed for MEDLINE]
- ☐ **15:** [Fukuzumi S, Inada O, Suenobu T.](#) Related Articles, Links

-  Direct detection of radical cations of NADH analogues.
J Am Chem Soc. 2002 Dec 11;124(49):14538-9. No abstract available.
PMID: 12465955 [PubMed - indexed for MEDLINE]
-  **16:** [Mathiesen C, Hagerhall C.](#) [Related Articles, Links](#)
-  Transmembrane topology of the NuoL, M and N subunits of NADH:quinone oxidoreductase and their homologues among membrane-bound hydrogenases and bona fide antiporters.
Biochim Biophys Acta. 2002 Dec 2;1556(2-3):121-32.
PMID: 12460669 [PubMed - indexed for MEDLINE]
-  **17:** [Bogachev AV, Bertsova YV, Ruuge EK, Wikstrom M, Verkhovsky MI.](#) [Related Articles, Links](#)
-  Kinetics of the spectral changes during reduction of the Na⁺-motive NADH:quinone oxidoreductase from *Vibrio harveyi*.
Biochim Biophys Acta. 2002 Dec 2;1556(2-3):113-20.
PMID: 12460668 [PubMed - indexed for MEDLINE]
-  **18:** [Kimura S, Kawamura M, Iyanagi T.](#) [Related Articles, Links](#)
-  Role of Thr(66) in porcine NADH-cytochrome b5 reductase in catalysis and control of the rate-limiting step in electron transfer.
J Biol Chem. 2003 Feb 7;278(6):3580-9. Epub 2002 Nov 28.
PMID: 12459552 [PubMed - indexed for MEDLINE]
-  **19:** [Nixon JE, Wang A, Field J, Morrison HG, McArthur AG, Sogin ML, Loftus BJ, Samuelson J.](#) [Related Articles, Links](#)
-  Evidence for lateral transfer of genes encoding ferredoxins, nitroreductases, NADH oxidase, and alcohol dehydrogenase 3 from anaerobic prokaryotes to *Giardia lamblia* and *Entamoeba histolytica*.
Eukaryot Cell. 2002 Apr;1(2):181-90.
PMID: 12455953 [PubMed - indexed for MEDLINE]
-  **20:** [Neves AR, Ramos A, Costa H, van Swam II, Hugenholtz J, Kleerebezem M, de Vos W, Santos H.](#) [Related Articles, Links](#)
-  Effect of different NADH oxidase levels on glucose metabolism by *Lactococcus lactis*: kinetics of intracellular metabolite pools determined by in vivo nuclear magnetic resonance.
Appl Environ Microbiol. 2002 Dec;68(12):6332-42.
PMID: 12450858 [PubMed - indexed for MEDLINE]
-  **21:** [Morre DJ, Penel C, Greppin H, Morre DM.](#) [Related Articles, Links](#)
-  The plasma membrane-associated NADH oxidase of spinach leaves responds to blue light.
Int J Plant Sci. 2002 Jul;163(4):543-7.
PMID: 12448422 [PubMed - indexed for MEDLINE]
-  **22:** [Flemming D, Hellwig P, Friedrich T.](#) [Related Articles, Links](#)
-  Involvement of tyrosines 114 and 139 of subunit NuoB in the proton pathway around cluster N2 in *Escherichia coli* NADH:ubiquinone oxidoreductase.
J Biol Chem. 2003 Jan 31;278(5):3055-62. Epub 2002 Nov 20.
PMID: 12446673 [PubMed - indexed for MEDLINE]
-  **23:** [Kumar P, Pai K, Pandey HP, Sundar S.](#) [Related Articles, Links](#)
- NADH-oxidase, NADPH-oxidase and myeloperoxidase activity of

-  visceral leishmaniasis patients.
J Med Microbiol. 2002 Oct;51(10):832-6.
PMID: 12435061 [PubMed - indexed for MEDLINE]
- ☐ **24:** [Harrison M, Singh SM.](#) Related Articles, Links
 Genetics and differential expression of NADH:ubiquinone oxidoreductase B8 subunit in brains of genetic strains of mice differing in voluntary alcohol consumption.
Biochim Biophys Acta. 2002 Dec 12;1579(2-3):164-72.
PMID: 12427551 [PubMed - indexed for MEDLINE]
- ☐ **25:** [Holtz KM, Rockwell S, Tomasz M, Sartorelli AC.](#) Related Articles, Links
 Nuclear overexpression of NADH:cytochrome b5 reductase activity increases the cytotoxicity of mitomycin C (MC) and the total number of MC-DNA adducts in Chinese hamster ovary cells.
J Biol Chem. 2003 Feb 14;278(7):5029-34. Epub 2002 Nov 6.
PMID: 12424239 [PubMed - indexed for MEDLINE]
- ☐ **26:** [Bandeiras TM, Salgueiro C, Kletzin A, Gomes CM, Teixeira M.](#) Related Articles, Links
 *Acidianus ambivalens* type-II NADH dehydrogenase: genetic characterisation and identification of the flavin moiety as FMN.
FEBS Lett. 2002 Nov 6;531(2):273-7.
PMID: 12417325 [PubMed - indexed for MEDLINE]
- ☐ **27:** [Hanley PJ, Ray J, Brandt U, Daut J.](#) Related Articles, Links
 Halothane, isoflurane and sevoflurane inhibit NADH:ubiquinone oxidoreductase (complex I) of cardiac mitochondria.
J Physiol. 2002 Nov 1;544(Pt 3):687-93.
PMID: 12411515 [PubMed - indexed for MEDLINE]
- ☐ **28:** [Reichenbach-Klinke R, Kruppa M, Konig B.](#) Related Articles, Links
 NADH model systems functionalized with Zn(II)-cyclen as flavin binding site-structure dependence of the redox reaction within reversible aggregates.
J Am Chem Soc. 2002 Nov 6;124(44):12999-3007.
PMID: 12405826 [PubMed - indexed for MEDLINE]
- ☐ **29:** [Nadlinger K, Westenthaler W, Storga-Tomic D, Birkmayer JG.](#) Related Articles, Links
 Extracellular metabolism of NADH by blood cells correlates with intracellular ATP levels.
Biochim Biophys Acta. 2002 Nov 14;1573(2):177-82.
PMID: 12399028 [PubMed - indexed for MEDLINE]
- ☐ **30:** [Vasse JL, Levacher V, Bourguignon J, Dupas G.](#) Related Articles, Links
 Atropoisomeric quinolinium salt promoting the access to both enantiomeric forms of methyl mandelate: a versatile NADH mimic.
Chem Commun (Camb). 2002 Oct 7;(19):2256-7.
PMID: 12398004 [PubMed - indexed for MEDLINE]
- ☐ **31:** [Percy MJ, Gillespie MJ, Savage G, Hughes AE, McMullin MF, Lappin TR.](#) Related Articles, Links
 Familial idiopathic methemoglobinemia revisited: original cases reveal 2 novel mutations in NADH-cytochrome b5 reductase.
Blood. 2002 Nov 15;100(10):3447-9. Epub 2002 Jul 5.

PMID: 12393396 [PubMed - indexed for MEDLINE]

- ☐ **32:** [Cocco T](#), [Cutechchia G](#), [Montedoro G](#), [Lorusso M](#). Related Articles, Links



The antihypertensive drug carvedilol inhibits the activity of mitochondrial NADH-ubiquinone oxidoreductase.
J Bioenerg Biomembr. 2002 Aug;34(4):251-8.
PMID: 12392188 [PubMed - indexed for MEDLINE]

- ☐ **33:** [Liu FQ](#), [Zhang JR](#). Related Articles, Links



Effect of NADH against liver cell line L02 apoptosis induced by UVB irradiation.
Di Yi Jun Yi Da Xue Xue Bao. 2002 Mar;22(3):232-4.
PMID: 12390773 [PubMed - indexed for MEDLINE]

- ☐ **34:** [Birkmayer GD](#), [Kay GG](#), [Vurre E](#). Related Articles, Links



[Stabilized NADH (ENADA) improves jet lag-induced cognitive performance deficit]
Wien Med Wochenschr. 2002;152(17-18):450-4. German.
PMID: 12385067 [PubMed - indexed for MEDLINE]

- ☐ **35:** [Elmore CL](#), [Porter TD](#). Related Articles, Links



Modification of the nucleotide cofactor-binding site of cytochrome P-450 reductase to enhance turnover with NADH in Vivo.
J Biol Chem. 2002 Dec 13;277(50):48960-4. Epub 2002 Oct 14.
PMID: 12381719 [PubMed - indexed for MEDLINE]

- ☐ **36:** [Prasad GS](#), [Wahlberg M](#), [Sridhar V](#), [Sundaresan V](#), [Yamaguchi M](#), [Hatefi Y](#), [Stout CD](#). Related Articles, Links



Crystal structures of transhydrogenase domain I with and without bound NADH.
Biochemistry. 2002 Oct 22;41(42):12745-54.
PMID: 12379117 [PubMed - indexed for MEDLINE]

- ☐ **37:** [Tan C](#), [Tuch BE](#), [Tu J](#), [Brown SA](#). Related Articles, Links



Role of NADH shuttles in glucose-induced insulin secretion from fetal beta-cells.
Diabetes. 2002 Oct;51(10):2989-96. Erratum in: *Diabetes* 2003 Jan;52(1):224.
PMID: 12351438 [PubMed - indexed for MEDLINE]

- ☐ **38:** [Drose S](#), [Zwicker K](#), [Brandt U](#). Related Articles, Links













Full recovery of the NADH:ubiquinone activity of complex I (NADH:ubiquinone oxidoreductase) from *Yarrowia lipolytica* by the addition of phospholipids.
Biochim Biophys Acta. 2002 Oct 3;1556(1):65-72.
PMID: 12351219 [PubMed - indexed for MEDLINE]

- ☐ **39:** [Maklashina E](#), [Sher Y](#), [Zhou HZ](#), [Gray MO](#), [Karlner JS](#), [Cecchini G](#). Related Articles, Links



Effect of anoxia/reperfusion on the reversible active/de-active transition of NADH-ubiquinone oxidoreductase (complex I) in rat heart.
Biochim Biophys Acta. 2002 Oct 3;1556(1):6-12.
PMID: 12351213 [PubMed - indexed for MEDLINE]

- ☐ **40:** [Fang J](#), [Beattie DS](#). Related Articles, Links

-  Rotenone-insensitive NADH dehydrogenase is a potential source of superoxide in procyclic *Trypanosoma brucei* mitochondria. *Mol Biochem Parasitol.* 2002 Aug 28;123(2):135-42. PMID: 12270629 [PubMed - indexed for MEDLINE]
- ☐ **41:** [Eto K, Kadowaki T.](#) [Related Articles, Links](#)
-  [Role of NADH shuttle system in glucose-stimulated insulin secretion] *Nippon Rinsho.* 2002 Jul;60 Suppl 7:190-207. Review. Japanese. No abstract available. PMID: 12238047 [PubMed - indexed for MEDLINE]
- ☐ **42:** [Seo BB, Nakamaru-Ogiso E, Flotte TR, Yagi T, Matsuno-Yagi A.](#) [Related Articles, Links](#)
-  A single-subunit NADH-quinone oxidoreductase renders resistance to mammalian nerve cells against complex I inhibition. *Mol Ther.* 2002 Sep;6(3):336-41. Erratum in: *Mol Ther.* 2003 Jun;7(6):859. PMID: 12231169 [PubMed - indexed for MEDLINE]
- ☐ **43:** [Yano T.](#) [Related Articles, Links](#)
-  The energy-transducing NADH: quinone oxidoreductase, complex I. *Mol Aspects Med.* 2002 Oct;23(5):345-68. Review. PMID: 12231006 [PubMed - indexed for MEDLINE]
- ☐ **44:** [Denicola A, Rubbo H, Haden L, Turrens JF.](#) [Related Articles, Links](#)
-  Extramitochondrial localization of NADH-fumarate reductase in trypanosomatids. *Comp Biochem Physiol B Biochem Mol Biol.* 2002 Sep;133(1):23-7. PMID: 12223208 [PubMed - indexed for MEDLINE]
- ☐ **45:** [Videira A, Duarte M.](#) [Related Articles, Links](#)
-  From NADH to ubiquinone in *Neurospora* mitochondria. *Biochim Biophys Acta.* 2002 Sep 10;1555(1-3):187-91. Review. PMID: 12206913 [PubMed - indexed for MEDLINE]
- ☐ **46:** [Olek RA, Antosiewicz J, Caulini GC, Falcioni G.](#) [Related Articles, Links](#)
-  Effect of NADH on the redox state of human hemoglobin. *Clin Chim Acta.* 2002 Oct;324(1-2):129-34. PMID: 12204434 [PubMed - indexed for MEDLINE]
- ☐ **47:** [Buchner M, Huber R, Sturchler-Pierrat C, Staufenbiel M, Riepe MW.](#) [Related Articles, Links](#)
-  Impaired hypoxic tolerance and altered protein binding of NADH in presymptomatic APP23 transgenic mice. *Neuroscience.* 2002;114(2):285-9. PMID: 12204198 [PubMed - indexed for MEDLINE]
- ☐ **48:** [Huang GL, Zhang G, Gao Y, Zhu JW.](#) [Related Articles, Links](#)
-  [Role of NADH-cytochrome b(5) reductase in biosynthesis of thyroid hydrogen peroxide] *Sheng Li Xue Bao.* 2002 Aug 25;54(4):349-53. Chinese. PMID: 12195287 [PubMed - in process]
- ☐ **49:** [Kotlyar AB, Borovok N.](#) [Related Articles, Links](#)
-  NADH oxidation and NAD⁺ reduction catalysed by tightly coupled inside-out vesicles from *Paracoccus denitrificans*. *Eur J Biochem.* 2002 Aug;269(16):4020-4.

PMID: 12180978 [PubMed - indexed for MEDLINE]

- ☐ **50:** [Rapisarda VA, Chehin RN, De Las Rivas J, Rodriguez-Montelongo L, Farias RN, Massa EM.](#) Related Articles, Links



Evidence for Cu(I)-thiolate ligation and prediction of a putative copper-binding site in the Escherichia coli NADH dehydrogenase-2.
Arch Biochem Biophys. 2002 Sep 1;405(1):87-94.
PMID: 12176061 [PubMed - indexed for MEDLINE]

- ☐ **51:** [Magnitsky S, Touloukhanova L, Yano T, Sled VD, Hagerhall C, Grivennikova VG, Burbaev DS, Vinogradov AD, Ohnishi T.](#) Related Articles, Links



EPR characterization of ubisemiquinones and iron-sulfur cluster N2, central components of the energy coupling in the NADH-ubiquinone oxidoreductase (complex I) in situ.
J Bioenerg Biomembr. 2002 Jun;34(3):193-208.
PMID: 12171069 [PubMed - indexed for MEDLINE]

- ☐ **52:** [Noda M, Yamashita S, Takahashi N, Eto K, Shen LM, Izumi K, Daniel S, Tsubamoto Y, Nemoto T, Iino M, Kasai H, Sharp GW, Kadowaki T.](#) Related Articles, Links



Switch to anaerobic glucose metabolism with NADH accumulation in the beta-cell model of mitochondrial diabetes. Characteristics of betaHC9 cells deficient in mitochondrial DNA transcription.
J Biol Chem. 2002 Nov 1;277(44):41817-26. Epub 2002 Aug 6.
PMID: 12169697 [PubMed - indexed for MEDLINE]

- ☐ **53:** [Martin-Romero FJ, Garcia-Martin E, Gutierrez-Merino C.](#) Related Articles, Links



Inhibition of oxidative stress produced by plasma membrane NADH oxidase delays low-potassium-induced apoptosis of cerebellar granule cells.
J Neurochem. 2002 Aug;82(3):705-15.
PMID: 12153494 [PubMed - indexed for MEDLINE]

- ☐ **54:** [Martin-Romero FJ, Gutierrez-Martin Y, Henao F, Gutierrez-Merino C.](#) Related Articles, Links



The NADH oxidase activity of the plasma membrane of synaptosomes is a major source of superoxide anion and is inhibited by peroxynitrite.
J Neurochem. 2002 Aug;82(3):604-14.
PMID: 12153484 [PubMed - indexed for MEDLINE]

- ☐ **55:** [Zu Y, Di Bernardo S, Yagi T, Hirst J.](#) Related Articles, Links



Redox properties of the [2Fe-2S] center in the 24 kDa (NQO2) subunit of NADH:ubiquinone oxidoreductase (complex I).
Biochemistry. 2002 Aug 6;41(31):10056-69.
PMID: 12146970 [PubMed - indexed for MEDLINE]

- ☐ **56:** [Besteiro S, Biran M, Biteau N, Coustou V, Baltz T, Canioni P, Bringaard F.](#) Related Articles, Links



Succinate secreted by Trypanosoma brucei is produced by a novel and unique glycosomal enzyme, NADH-dependent fumarate reductase.
J Biol Chem. 2002 Oct 11;277(41):38001-12. Epub 2002 Jul 22.
PMID: 12138089 [PubMed - indexed for MEDLINE]

- ☐ **57:** [Zakharova NV.](#) Related Articles, Links



Kinetics of the transhydrogenase reaction catalyzed by mitochondrial NADH:ubiquinone oxidoreductase (complex I).

Biochemistry (Mosc). 2002 Jun;67(6):651-61.
PMID: 12126472 [PubMed - indexed for MEDLINE]

- ☐ **58:** [Anderson RE, Meyer FB.](#) Related Articles, Links



In vivo fluorescent imaging of NADH redox state in brain.
Methods Enzymol. 2002;352:482-94. No abstract available.
PMID: 12125373 [PubMed - indexed for MEDLINE]

- ☐ **59:** [Brandes R, Bers DM.](#) Related Articles, Links



Simultaneous measurements of mitochondrial NADH and Ca(2+) during increased work in intact rat heart trabeculae.
Biophys J. 2002 Aug;83(2):587-604.
PMID: 12124250 [PubMed - indexed for MEDLINE]

- ☐ **60:** [Barquera B, Zhou W, Morgan JE, Gennis RB.](#) Related Articles, Links



Riboflavin is a component of the Na⁺-pumping NADH-quinone oxidoreductase from *Vibrio cholerae*.
Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10322-4. Epub 2002 Jul 16.
PMID: 12122213 [PubMed - indexed for MEDLINE]

- ☐ **61:** [Camacho Carvajal MM, Wijffes AH, Mulders IH, Lugtenberg BJ, Bloemberg GV.](#) Related Articles, Links



Characterization of NADH dehydrogenases of *Pseudomonas fluorescens* WCS365 and their role in competitive root colonization.
Mol Plant Microbe Interact. 2002 Jul;15(7):662-71.
PMID: 12118882 [PubMed - indexed for MEDLINE]

- ☐ **62:** [Zhang L, Kudo T, Takaya N, Shoun H.](#) Related Articles, Links



The B' helix determines cytochrome P450nor specificity for the electron donors NADH and NADPH.
J Biol Chem. 2002 Sep 13;277(37):33842-7. Epub 2002 Jul 8.
PMID: 12105197 [PubMed - indexed for MEDLINE]

- ☐ **63:** [McDonough JA, Bhattacharjee V, Sadlon T, Hostetter MK.](#) Related Articles, Links



Involvement of *Candida albicans* NADH dehydrogenase complex I in filamentation.
Fungal Genet Biol. 2002 Jul;36(2):117-27.
PMID: 12081465 [PubMed - indexed for MEDLINE]

- ☐ **64:** [Yeh JJ, Claiborne A.](#) Related Articles, Links



Crystal structures of oxidized and reduced forms of NADH peroxidase.
Methods Enzymol. 2002;353:44-54.
PMID: 12078517 [PubMed - indexed for MEDLINE]

- ☐ **65:** [Rex A, Hentschke MP, Fink H.](#) Related Articles, Links



Bioavailability of reduced nicotinamide-adenine-dinucleotide (NADH) in the central nervous system of the anaesthetized rat measured by laser-induced fluorescence spectroscopy.
Pharmacol Toxicol. 2002 Apr;90(4):220-5.
PMID: 12076318 [PubMed - indexed for MEDLINE]


- ☐ **66:** [Taylor LM, Andrew Aquilina J, Jamie JF, Truscott RJ.](#) Related Articles, Links



Glutathione and NADH, but not ascorbate, protect lens proteins from modification by UV filters.

Exp Eye Res. 2002 Apr;74(4):503-11.
PMID: 12076094 [PubMed - indexed for MEDLINE]

- ☐ **67:** Valdez LB, Actis-Goretta L, Boveris A. Related Articles, Links



Polyphenols in red wines prevent NADH oxidation induced by peroxynitrite.

Ann N Y Acad Sci. 2002 May;957:274-8.
PMID: 12074980 [PubMed - indexed for MEDLINE]

- ☐ **68:** Boveris A, Valdez L, Alvarez S. Related Articles, Links



Inhibition by wine polyphenols of peroxynitrite-initiated chemiluminescence and NADH oxidation.

Ann N Y Acad Sci. 2002 May;957:90-102. Review.
PMID: 12074964 [PubMed - indexed for MEDLINE]

- ☐ **69:** Herles C, Braune A, Blaut M. Related Articles, Links



Purification and characterization of an NADH oxidase from *Eubacterium ramulus*.

Arch Microbiol. 2002 Jul;178(1):71-4. Epub 2002 May 7.
PMID: 12070772 [PubMed - indexed for MEDLINE]

- ☐ **70:** Muhlenhoff U, Richhardt N, Gerber J, Lill R. Related Articles, Links



Characterization of iron-sulfur protein assembly in isolated mitochondria. A requirement for ATP, NADH, and reduced iron.

J Biol Chem. 2002 Aug 16;277(33):29810-6. Epub 2002 Jun 13.
PMID: 12065597 [PubMed - indexed for MEDLINE]

- ☐ **71:** Riess ML, Camara AK, Chen Q, Novalija E, Rhodes SS, Stowe DF. Related Articles, Links



Altered NADH and improved function by anesthetic and ischemic preconditioning in guinea pig intact hearts.

Am J Physiol Heart Circ Physiol. 2002 Jul;283(1):H53-60.
PMID: 12063274 [PubMed - indexed for MEDLINE]

- ☐ **72:** Svensson AS, Johansson FI, Moller IM, Rasmusson AG. Related Articles, Links



Cold stress decreases the capacity for respiratory NADH oxidation in potato leaves.

FEBS Lett. 2002 Apr 24;517(1-3):79-82.
PMID: 12062413 [PubMed - indexed for MEDLINE]

- ☐ **73:** Hayashi M, Shibata N, Nakayama Y, Yoshikawa K, Unemoto T. Related Articles, Links



Korormicin insensitivity in *Vibrio alginolyticus* is correlated with a single point mutation of Gly-140 in the NqrB subunit of the Na(+)-translocating NADH-quinone reductase.

Arch Biochem Biophys. 2002 May 15;401(2):173-7.
PMID: 12054467 [PubMed - indexed for MEDLINE]










- ☐ **74:** Duarte M, Populo H, Videira A, Friedrich T, Schulte U. Related Articles, Links





















Disruption of iron-sulphur cluster N2 from NADH: ubiquinone oxidoreductase by site-directed mutagenesis.

Biochem J. 2002 Jun 15;364(Pt 3):833-9.
PMID: 12049648 [PubMed - indexed for MEDLINE]

- ☐ **75:** Jensen Jr KA Jr, Ryan ZC, Vanden Wymelenberg A, Cullen D, Hammel KE. Related Articles, Links

-  An NADH:quinone oxidoreductase active during biodegradation by the brown-rot basidiomycete *Gloeophyllum trabeum*.
Appl Environ Microbiol. 2002 Jun;68(6):2699-703.
PMID: 12039722 [PubMed - indexed for MEDLINE]
- ☐ **76:** Raijmakers MT, Roes EM, Steegers EA, Peters WH. Related Articles, Links
 The C242T-polymorphism of the NADPH/NADH oxidase gene p22phox subunit is not associated with pre-eclampsia.
J Hum Hypertens. 2002 Jun;16(6):423-5.
PMID: 12037698 [PubMed - indexed for MEDLINE]
- ☐ **77:** Deguchi T, Matsubara M, Nishida T. Related Articles, Links
 NADH oxidation by manganese peroxidase with or without alpha-hydroxy acid.
Biosci Biotechnol Biochem. 2002 Apr;66(4):717-21.
PMID: 12036041 [PubMed - indexed for MEDLINE]
- ☐ **78:** Hammen PK, Allali-Hassani A, Hallenga K, Hurley TD, Weiner H. Related Articles, Links
 Multiple conformations of NAD and NADH when bound to human cytosolic and mitochondrial aldehyde dehydrogenase.
Biochemistry. 2002 Jun 4;41(22):7156-68.
PMID: 12033950 [PubMed - indexed for MEDLINE]
- ☐ **79:** Pahlman IL, Larsson C, Averet N, Bunoust O, Boubekeur S, Gustafsson L, Rigoulet M. Related Articles, Links
 Kinetic regulation of the mitochondrial glycerol-3-phosphate dehydrogenase by the external NADH dehydrogenase in *Saccharomyces cerevisiae*.
J Biol Chem. 2002 Aug 2;277(31):27991-5. Epub 2002 May 24.
PMID: 12032156 [PubMed - indexed for MEDLINE]
- ☐ **80:** Batchelor RH, Zhou M. Related Articles, Links
 A resorufin-based fluorescent assay for quantifying NADH.
Anal Biochem. 2002 Jun 1;305(1):118-9. No abstract available.
PMID: 12018954 [PubMed - indexed for MEDLINE]
- ☐ **81:** Nakashima Y, Shinzawa-Itoh K, Watanabe K, Naoki K, Hano N, Yoshikawa S. Related Articles, Links
 The second coenzyme Q1 binding site of bovine heart NADH: coenzyme Q oxidoreductase.
J Bioenerg Biomembr. 2002 Apr;34(2):89-94.
PMID: 12018892 [PubMed - indexed for MEDLINE]
- ☐ **82:** Murata M, Kawanishi S. Related Articles, Links
 Oxidation of 5'-site guanine at GG and GGG sequences induced by a metabolite of carcinogenic heterocyclic amine PhIP in the presence of Cu (II) and NADH.
Carcinogenesis. 2002 May;23(5):855-60.
PMID: 12016160 [PubMed - indexed for MEDLINE]
- ☐ **83:** Miki T. Related Articles, Links
 [Mitochondrial complex I (NADH-ubiquinone oxidoreductase)]
Nippon Rinsho. 2002 Apr;60 Suppl 4:135-8. Review. Japanese. No abstract available.
PMID: 12013836 [PubMed - indexed for MEDLINE]

-  **84:** [Neves AR, Ventura R, Mansour N, Shearman C, Gasson MJ, Maycock C, Ramos A, Santos H.](#) [Related Articles, Links](#)
-  Is the glycolytic flux in *Lactococcus lactis* primarily controlled by the redox charge? Kinetics of NAD(+) and NADH pools determined in vivo by ¹³C NMR.
J Biol Chem. 2002 Aug 2;277(31):28088-98. Epub 2002 May 13.
PMID: 12011086 [PubMed - indexed for MEDLINE]
-  **85:** [Ellis EA, Guberski DL, Hutson B, Grant MB.](#) [Related Articles, Links](#)
-  Time course of NADH oxidase, inducible nitric oxide synthase and peroxynitrite in diabetic retinopathy in the BBZ/WOR rat.
Nitric Oxide. 2002 May;6(3):295-304.
PMID: 12009847 [PubMed - indexed for MEDLINE]
-  **86:** [Bartlett PN, Simon E, Toh CS.](#) [Related Articles, Links](#)
-  Modified electrodes for NADH oxidation and dehydrogenase-based biosensors.
Bioelectrochemistry. 2002 May 15;56(1-2):117-22.
PMID: 12009456 [PubMed - indexed for MEDLINE]
-  **87:** [Munteanu FD, Mano N, Kuhn A, Gorton L.](#) [Related Articles, Links](#)
-  Mediator-modified electrodes for catalytic NADH oxidation: high rate constants at interesting overpotentials.
Bioelectrochemistry. 2002 May 15;56(1-2):67-72.
PMID: 12009446 [PubMed - indexed for MEDLINE]
-  **88:** [Mayr P, Nidetzky B.](#) [Related Articles, Links](#)
-  Catalytic reaction profile for NADH-dependent reduction of aromatic aldehydes by xylose reductase from *Candida tenuis*.
Biochem J. 2002 Sep 15;366(Pt 3):889-99.
PMID: 12003638 [PubMed - indexed for MEDLINE]
-  **89:** [Sambongi Y, Nitta H, Ichihashi K, Futai M, Ueda I.](#) [Related Articles, Links](#)
-  A novel water-soluble Hantzsch 1,4-dihydropyridine compound that functions in biological processes through NADH regeneration.
J Org Chem. 2002 May 17;67(10):3499-501.
PMID: 12003566 [PubMed - indexed for MEDLINE]
-  **90:** [Li N, Yi FX, Spurrier JL, Bobrowitz CA, Zou AP.](#) [Related Articles, Links](#)
-  Production of superoxide through NADH oxidase in thick ascending limb of Henle's loop in rat kidney.
Am J Physiol Renal Physiol. 2002 Jun;282(6):F1111-9.
PMID: 11997328 [PubMed - indexed for MEDLINE]
-  **91:** [Itoh N, Matsuda M, Mabuchi M, Dairi T, Wang J.](#) [Related Articles, Links](#)
-  Chiral alcohol production by NADH-dependent phenylacetaldehyde reductase coupled with in situ regeneration of NADH.
Eur J Biochem. 2002 May;269(9):2394-402.
PMID: 11985623 [PubMed - indexed for MEDLINE]
-  **92:** [Krungkrai J, Kanchanarithsak R, Krungkrai SR, Rochanakij S.](#) [Related Articles, Links](#)
-  Mitochondrial NADH dehydrogenase from *Plasmodium falciparum* and *Plasmodium berghei*.

Exp Parasitol. 2002 Jan;100(1):54-61.
PMID: 11971654 [PubMed - indexed for MEDLINE]

- ☐ **93:** Morre DJ. [Related Articles, Links](#)



Preferential inhibition of the plasma membrane NADH oxidase (NOX) activity by diphenyleneiodonium chloride with NADPH as donor. Antioxid Redox Signal. 2002 Feb;4(1):207-12. PMID: 11970854 [PubMed - indexed for MEDLINE]

- ☐ **94:** O'Flaherty CM, Beorlegui NB, Beconi MT. [Related Articles, Links](#)



Lactate dehydrogenase-C4 is involved in heparin- and NADH-dependent bovine sperm capacitation. Andrologia. 2002 Apr;34(2):91-7. Erratum in: Andrologia. 2002 Dec;34(6):405. PMID: 11966575 [PubMed - indexed for MEDLINE]

- ☐ **95:** Tendi EA, Bosetti F, Dasgupta SF, Stella AM, Drieu K, Rapoport SL. [Related Articles, Links](#)



Ginkgo biloba extracts EGb 761 and bilobalide increase NADH dehydrogenase mRNA level and mitochondrial respiratory control ratio in PC12 cells. Neurochem Res. 2002 Apr;27(4):319-23. PMID: 11958534 [PubMed - indexed for MEDLINE]

- ☐ **96:** Cho N, Chueh PJ, Kim C, Caldwell S, Morre DM, Morre DJ. [Related Articles, Links](#)



Monoclonal antibody to a cancer-specific and drug-responsive hydroquinone (NADH) oxidase from the sera of cancer patients. Cancer Immunol Immunother. 2002 May;51(3):121-9. Epub 2002 Feb 27. PMID: 11941450 [PubMed - indexed for MEDLINE]

- ☐ **97:** Kahn AM, Allen JC, Zhang S. [Related Articles, Links](#)



Insulin increases NADH/NAD⁺ redox state, which stimulates guanylate cyclase in vascular smooth muscle. Am J Hypertens. 2002 Mar;15(3):273-9. PMID: 11939620 [PubMed - indexed for MEDLINE]

- ☐ **98:** Kao MC, Di Bernardo S, Matsuno-Yagi A, Yagi T. [Related Articles, Links](#)



Characterization of the membrane domain Nqo11 subunit of the proton-translocating NADH-quinone oxidoreductase of Paracoccus denitrificans. Biochemistry. 2002 Apr 2;41(13):4377-84. PMID: 11914084 [PubMed - indexed for MEDLINE]

- ☐ **99:** Barquera B, Hellwig P, Zhou W, Morgan JE, Hase CC, Gosink KK, Nilges M, Brueschoff PJ, Roth A, Lancaster CR, Gennis RB. [Related Articles, Links](#)





















Purification and characterization of the recombinant Na⁺-translocating NADH:quinone oxidoreductase from Vibrio cholerae. Biochemistry. 2002 Mar 19;41(11):3781-9. PMID: 11888296 [PubMed - indexed for MEDLINE]








- ☐ **100:** Chueh PJ, Kim C, Cho N, Morre DM, Morre DJ. [Related Articles, Links](#)



Molecular cloning and characterization of a tumor-associated, growth-related, and time-keeping hydroquinone (NADH) oxidase (tNOX) of the HeLa cell surface. Biochemistry. 2002 Mar 19;41(11):3732-41. PMID: 11888291 [PubMed - indexed for MEDLINE]

-  **101:** [MacDonald MJ, Kelley PC, Laclau M.](#) [Related Articles, Links](#)
 Histochemical evidence for pathways insulin cells use to oxidize glycolysis-derived NADH. *Metabolism*. 2002 Mar;51(3):318-21. PMID: 11887167 [PubMed - indexed for MEDLINE]
- 102:** [Lemeshko VV.](#) [Related Articles, Links](#)
 Cytochrome c sorption-desorption effects on the external NADH oxidation by mitochondria: experimental and computational study. *J Biol Chem*. 2002 May 17;277(20):17751-7. Epub 2002 Mar 8. PMID: 11886867 [PubMed - indexed for MEDLINE]
- 103:** [Bottcher B, Scheide D, Hesterberg M, Nagel-Steger L, Friedrich T.](#) [Related Articles, Links](#)
 A novel, enzymatically active conformation of the Escherichia coli NADH:ubiquinone oxidoreductase (complex I). *J Biol Chem*. 2002 May 17;277(20):17970-7. Epub 2002 Mar 5. PMID: 11880370 [PubMed - indexed for MEDLINE]
- 104:** [Kim C, Crane FL, Faulk WP, Morre DJ.](#) [Related Articles, Links](#)
 Purification and characterization of a doxorubicin-inhibited NADH-quinone (NADH-ferricyanide) reductase from rat liver plasma membranes. *J Biol Chem*. 2002 May 10;277(19):16441-7. Epub 2002 Mar 1. PMID: 11875069 [PubMed - indexed for MEDLINE]
- 105:** [Pantano S, Alber F, Lamba D, Carloni P.](#) [Related Articles, Links](#)
 NADH interactions with WT- and S94A-acyl carrier protein reductase from *Mycobacterium tuberculosis*: an ab initio study. *Proteins*. 2002 Apr 1;47(1):62-8. PMID: 11870865 [PubMed - indexed for MEDLINE]
- 106:** [Janiszewski M, Souza HP, Liu X, Pedro MA, Zweier JL, Laurindo FR.](#) [Related Articles, Links](#)
 Overestimation of NADH-driven vascular oxidase activity due to lucigenin artifacts. *Free Radic Biol Med*. 2002 Mar 1;32(5):446-53. PMID: 11864784 [PubMed - indexed for MEDLINE]
- 107:** [Fang J, Beattie DS.](#) [Related Articles, Links](#)
 Novel FMN-containing rotenone-insensitive NADH dehydrogenase from *Trypanosoma brucei* mitochondria: isolation and characterization. *Biochemistry*. 2002 Mar 5;41(9):3065-72. PMID: 11863445 [PubMed - indexed for MEDLINE]
- 108:** [Nakashima Y, Shinzawa-Itoh K, Watanabe K, Naoki K, Hano N, Yoshikawa S.](#) [Related Articles, Links](#)
 Steady-state kinetics of NADH:coenzyme Q oxidoreductase isolated from bovine heart mitochondria. *J Bioenerg Biomembr*. 2002 Feb;34(1):11-9. PMID: 11860176 [PubMed - indexed for MEDLINE]
- 109:** [Papa S, Sardanelli AM, Scacco S, Petruzzella V, Technikova-Dobrova Z, Vergari R, Signorile A.](#) [Related Articles, Links](#)
The NADH: ubiquinone oxidoreductase (complex I) of the mammalian

-  respiratory chain and the cAMP cascade.
J Bioenerg Biomembr. 2002 Feb;34(1):1-10. Review.
PMID: 11860175 [PubMed - indexed for MEDLINE]
- ☐ **110:** Steuber J, Rufibach M, Fritz G, Neese F, Dimroth P. Related Articles, Links
 Inactivation of the Na⁺-translocating NADH:ubiquinone oxidoreductase from *Vibrio alginolyticus* by reactive oxygen species.
Eur J Biochem. 2002 Feb;269(4):1287-92.
PMID: 11856363 [PubMed - indexed for MEDLINE]
- ☐ **111:** Scheide D, Huber R, Friedrich T. Related Articles, Links
 The proton-pumping NADH:ubiquinone oxidoreductase (complex I) of *Aquifex aeolicus*.
FEBS Lett. 2002 Feb 13;512(1-3):80-4.
PMID: 11852056 [PubMed - indexed for MEDLINE]
- ☐ **112:** Voronina S, Sukhomlin T, Johnson PR, Erdemli G, Petersen OH, Tepikin A. Related Articles, Links
 Correlation of NADH and Ca²⁺ signals in mouse pancreatic acinar cells.
J Physiol. 2002 Feb 15;539(Pt 1):41-52.
PMID: 11850500 [PubMed - indexed for MEDLINE]
- ☐ **113:** Zhang Q, Piston DW, Goodman RH. Related Articles, Links
 Regulation of corepressor function by nuclear NADH.
Science. 2002 Mar 8;295(5561):1895-7. Epub 2002 Feb 14.
PMID: 11847309 [PubMed - indexed for MEDLINE]
- ☐ **114:** Lancien M, Martin M, Hsieh MH, Leustek T, Goodman H, Coruzzi GM. Related Articles, Links
 Arabidopsis glt1-T mutant defines a role for NADH-GOGAT in the non-photorespiratory ammonium assimilatory pathway.
Plant J. 2002 Feb;29(3):347-58.
PMID: 11844111 [PubMed - indexed for MEDLINE]
- ☐ **115:** Joet T, Cournac L, Peltier G, Havaux M. Related Articles, Links
 Cyclic electron flow around photosystem I in C(3) plants. In vivo control by the redox state of chloroplasts and involvement of the NADH-dehydrogenase complex.
Plant Physiol. 2002 Feb;128(2):760-9.
PMID: 11842179 [PubMed - indexed for MEDLINE]
- ☐ **116:** Ammendola R, Ruocchio MR, Chirico G, Russo L, De Felice C, Esposito F, Russo T, Cimino F. Related Articles, Links
 Inhibition of NADH/NADPH oxidase affects signal transduction by growth factor receptors in normal fibroblasts.
Arch Biochem Biophys. 2002 Jan 15;397(2):253-7.
PMID: 11795879 [PubMed - indexed for MEDLINE]
- ☐ **117:** Reynolds CM, Meyer J, Poole LB. Related Articles, Links
 An NADH-dependent bacterial thioredoxin reductase-like protein in conjunction with a glutaredoxin homologue form a unique peroxiredoxin (AhpC) reducing system in *Clostridium pasteurianum*.
Biochemistry. 2002 Feb 12;41(6):1990-2001.
PMID: 11827546 [PubMed - indexed for MEDLINE]

- ☐ **118:** [Morre DJ, Lawler J, Wang S, Keenan TW, Morre DM.](#) [Related Articles, Links](#)
 Entrainment in solution of an oscillating NADH oxidase activity from the bovine milk fat globule membrane with a temperature-compensated period length suggestive of an ultradian time-keeping (clock) function. *Biochim Biophys Acta*. 2002 Feb 10;1559(1):10-20. PMID: 11825584 [PubMed - indexed for MEDLINE]
- ☐ **119:** [Kim YK, Lee MS, Son SM, Kim JJ, Lee WS, Rhim BY, Hong KW, Kim CD.](#) [Related Articles, Links](#)
 Vascular NADH oxidase is involved in impaired endothelium-dependent vasodilation in OLETF rats, a model of type 2 diabetes. *Diabetes*. 2002 Feb;51(2):522-7. PMID: 11812764 [PubMed - indexed for MEDLINE]
- ☐ **120:** [Cook SA, Shiemke AK.](#) [Related Articles, Links](#)
 Evidence that a type-2 NADH:quinone oxidoreductase mediates electron transfer to particulate methane monooxygenase in *Methylococcus capsulatus*. *Arch Biochem Biophys*. 2002 Feb 1;398(1):32-40. PMID: 11811946 [PubMed - indexed for MEDLINE]
- ☐ **121:** [Higuchi T, Takeda Y, Hashimoto M, Nagano O, Hirakawa M.](#) [Related Articles, Links](#)
 Dynamic changes in cortical NADH fluorescence and direct current potential in rat focal ischemia: relationship between propagation of recurrent depolarization and growth of the ischemic core. *J Cereb Blood Flow Metab*. 2002 Jan;22(1):71-9. PMID: 11807396 [PubMed - indexed for MEDLINE]
- ☐ **122:** [Fontaine L, Meynial-Salles I, Girbal L, Yang X, Croux C, Soucaille P.](#) [Related Articles, Links](#)
 Molecular characterization and transcriptional analysis of adhE2, the gene encoding the NADH-dependent aldehyde/alcohol dehydrogenase responsible for butanol production in alcohologenic cultures of *Clostridium acetobutylicum* ATCC 824. *J Bacteriol*. 2002 Feb;184(3):821-30. PMID: 11790753 [PubMed - indexed for MEDLINE]
- ☐ **123:** [Diction SP, Faraci FM.](#) [Related Articles, Links](#)
 Effects of NADH and NADPH on superoxide levels and cerebral vascular tone. *Am J Physiol Heart Circ Physiol*. 2002 Feb;282(2):H688-95. PMID: 11788419 [PubMed - indexed for MEDLINE]
- ☐ **124:** [Nakamaru-Ogiso E, Yano T, Ohnishi T, Yagi T.](#) [Related Articles, Links](#)
 Characterization of the iron-sulfur cluster coordinated by a cysteine cluster motif (CXXCXXXXCX27C) in the Nqo3 subunit in the proton-translocating NADH-quinone oxidoreductase (NDH-1) of *Thermus thermophilus* HB-8. *J Biol Chem*. 2002 Jan 18;277(3):1680-8. Epub 2001 Nov 9. PMID: 11704668 [PubMed - indexed for MEDLINE]

Display Summary

Show 200

Sort by

Send to

Write to the Help Desk
NCBI | NLM | NIH

Department of Health & Human Services
[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Sep 5 2006 08:10:00